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Abstract 
Introduction: Rheumatoid (RA) and psoriatic arthritis (PsA) are common diseases affecting about 
1% of population and are characterized by chronic joint inflammation. Although both have peculiar 
features such as the presence of specific autoantibodies, in the case of RA, or involvement of skin 
and nails, in the case of PsA, they show many similarities. Joint distribution, clinical and 
radiological manifestations may be so identical -especially early in the beginning of disease- that 
differentiation gets impossible except for hard to gain biopsy specimens showing distinct 
vascularization patterns for both diseases. Among all forms of arthritides, RA has the worst 
outcome. Early identification and treatment is considered imperative. Synovitis in RA is consistent 
with inflammation, synovial hyperplasia and neovascularization, that correlates with disease 
activity, aggressiveness and joint destruction. Synovitis is in RA the primary event, in PsA 
secondary to inflammation of entheses, capsules and other perisynovial structures. In RA 
inflammatory vessels are homogenously distributed in synovia and show linear and branching  
architecture. In PsA vessel distribution is more inhomogeneous in synovial and perisynovial regions 
and are more tortuous and bushy. Contrast enhanced ultrasonography (CEUS) has been proven to 
be a very sensitive method in assessing inflammatory neovascularization equivalent to magnetic 
resonance imaging. The possibility to discriminate RA from PsA with the help of vascularization 
patterns detected non-invasively by CEUS has not yet been tested.  
Material and methods: 107 outclinic patients presenting arthritis of finger joints were recruited, 56 
with defined RA and 51 with defined PsA. The most active joint was chosen for CEUS exams. The 
hands were water-immersed and steady probe was used to increase image quality. While contrast 
bolus injection, contrast tune imaging with low mechanical index was used for image acquisition. 
CEUS images were validated manually by radiologists for both CEUS grade and presumptive 
diagnosis of RA or PsA considering histopathological differences. RA was assumed to present with 
a more homogenous and synovial enhancement and faster time of contrast appearance due to linear 
and branching vessel architecture, whereas PsA with inhomogeneous enhancement both in synovial 
and perisynovial region representing entheses and capsules, and later contrast appearance due to 
tortuous, bushy vessels. Further contrast kinetics were analyzed by ad hoc automated analysis 
software including a new developed pixel-based and a region-based procedure similar to available 
commercialized systems. Contrast kinetics of each image pixel was described by a gamma curve 
f(t)=A(t-t0)a×e(t-t0)/b, and 98 flow parameters in synovial and perisynovial tissue were derived and 
analyzed. 37 of these parameters proved to be significantly different (p<0.05) between RA and PsA 
populations. A linear discriminant classifier was trained to identify the transformation optimizing 
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the linear separability of the two groups, and each patient was assigned to RA or PsA with a 
Bayesian classification algorithm providing the a posteriori probability to belong to the RA or PsA 
group. The diagnostic power of the identified vascularization pattern was tested by means of leave-
one-out analysis. Correlations between flow parameters and clinical data were calculated. 
Results: Accuracy of automated pixel-based CEUS analysis to discriminate RA from PsA was 0.93 
in training and 0.83 in test conditions, by adding data about rheumatoid factor and anti-cyclic 
citrullinated peptides accuracy was enhanced to 0.99 and 0.93 respectively. Accuracies of manual 
(0.69) and region-based automated analysis (0.61) were definitively lower. The best flow 
parameters for the construction of vascularization pattern discriminating between RA and PsA were 
mean synovial raise time (faster in RA), mean synovial raise constant (lower in RA), time to 
synovial peak (faster in RA), mean synovial peak value (higher in RA), synovial active regions 
(more numerous in RA), mean dimension of synovial active regions (greater in RA), synovial and 
perisynovial blood volume (both greater in RA), synovia/perisynovia blood volume and flow (all 
higher in RA).  No correlations were identified between flow parameter and clinical data. 
Conclusion: Dynamic automated synovial imaging (DASI) is consistent with a new tool to study 
directly vascularization patterns in synovitis, which was possible only by histologic specimens up to 
now. DASI is highly effective to differentiate RA from PsA by identifying distinct vascularization 
patterns. 
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Riassunto 
Introduzione: L’artrite reumatoide (AR) e l’artrite psoriasica (APs) sono delle affezioni comuni, 
che colpiscono l% della popolazione generale, e sono caratterizzate dalla infiammazione articolare 
cronica. Anche se presentano delle peculiarità distintive, quali la presenza di autoanticorpi, nel caso 
dell’AR, e il coinvolgimento della pelle e delle unghie, nel caso dell’APs, entrambe le forme di 
artrite presentano molti elementi in comune. La distribuzione articolare e le manifestazioni cliniche 
e radiologiche possono essere identiche, soprattutto nelle fasi inziali della malattia, cosicché la 
distinzione diventa impossibile, se non attraverso lo studio istologico della membrana sinoviale, che 
presenta un tipo di vascolarizzazione specifica per le due artriti, ma però non è facilmente 
reperibile.  Tra le varie artriti l’AR ha la prognosi più sfavorevole e pertanto una diagnosi e terapia 
precoci sono imperative. La sinovite reumatoide consiste di infiammazione, iperplasia sinoviale e 
neovascolarizzazione, che correla con l’attività di malattia, aggressività e distruzione articolare. 
Nell’AR la sinovite è l’evento primitivo, invece nella APs è secondaria all’infiammazione delle 
entesi, capsule e altre strutture peri-articolari. Nell’AR i vasi infiammatori di morfologia retta e 
arborescente sono omogeneamente disposti nella sinovia. Nell’APs invece sono tortuosi e “a 
cespuglio” e la loro distribuzione è disomogenea nella sinovia e peri-sinovia. L’ecografia con 
mezzo di contrasto (contrast-enhanced ultrasound, CEUS) è una metodica per lo studio vascolare, 
soprattutto della neovascolarizzazione infiammatoria, molto sensibile raggiungendo il livello della 
risonanza magnetica. La possibilità di discriminare con la CEUS l’AR dalla APs attraverso l’analisi 
non-invasiva degli specifici tipi di vascolarizzazione non è ancora stato studiata 
Materiali and metodi: 107 pazienti afferenti alla nostra unità di Reumatologia ed affetti da artrite 
delle mani sono stati reclutati. 56 erano stati diagnosticati come AR e 51 come APs. L’articolazione 
più attiva riferita dal paziente è stata scelta per l’esame CEUS.  Le mani sono state immersi in 
acqua usando una sonda fissa per migliorare la qualità di immagine. Durante l’iniezione di contrasto 
le immagini sono state acquisite tramite la modalità per contrasto, che hanno in utilizzo indici 
meccanici bassi. Le immagini CEUS sono state validate manualmente dai radiologici sia per il 
grado CEUS che per  la presunta diagnosi di artrite tendendo conto delle differenze istologiche note.   
Si assumeva che l’AR presentasse un rinforzo contrastografico sinoviale più omogeno e un tempo 
di arrivo del contrasto più breve dato la morfologia retta e arborescente dei vasi, mentre l’APs con 
un rinforzo disomogeneo sia nella zona sinoviale che in quella peri-sinoviale comprendenti le entesi 
e capsule, e  un arrivo del contrasto tardivo per i vasi tortuosi e “a cespuglio”. 
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Inoltre le cinetiche del contrasto sono state analizzate da un sistema analitico automatizzato 
programmato ad hoc per questo studio. Le analisi hanno compreso una procedura a base di singoli 
pixel, sviluppata ex novo, e a base di intere regioni, analoga a sistemi attualmente commercializzati.  
La cinetica dei singoli pixel è stata descritta tramite una curva f(t)=A(t-t0)a×e(t-t0)/b, e 98 
parametri di flusso diversi sono stati identificati ed analizzati nella zona sinoviale e peri-sinoviale. 
37 di questi parametri presentavano differenze significative tra pazienti con AR e APs (p<0.05). Un 
classificatore lineare discriminatore è stato allenato per identificare le trasformazioni necessarie per 
ottimizzare la separabilità lineare dei due gruppi. Ciascun paziente è stato assegnato al gruppo AR o 
APs attraverso un algoritmo di classificazione bayesiana per determinare la probabilità a posteriori 
di appartenere ad un gruppo invece che all’altro. La potenza diagnostica del prototipo di 
vascolarizzazione così creato è stata verificata tramite un’analisi “leave-one-out”. Infine 
correlazioni tra parametri di flusso CEUS e dati clinici sono stati ricercati.  
Risultati:  L’accuratezza nel discriminare pazienti con AR da quelli con APs è 0.93 per l’analisi 
CEUS automatizzata a base di pixel nella fase di allenamento e 0.83 nella fase di verifica. 
Aggiungendo i dati su fattore reumatoide ed anticorpi contro peptidi citrullinati ciclici l’accuratezza 
aumentava al 0.99 e 0.93 relativamente nella fase di allenamento e verifica. L’accuratezza 
dell’analisi CEUS manuale (0.69) e dell’analisi automatizzata a base di regioni (0.61) erano 
definitivamente più basse. I parametri di flusso contrastografico più importanti nella creazione del 
prototipo di vascolarizzazione discriminante tra AR e APs erano la velocità media di incremento 
sinoviale (più veloce in AR), la costante di incremento sinoviale (più basso in AR), il tempo al 
picco sinoviale (più veloce in AR), il valore medio del picco (più alto in AR), il numero delle 
regioni sinoviali attive (più numerose in AR), la dimensione media della regioni sinoviali attive (più 
grande in AR), il volume sanguigno sinoviale e peri-sinoviale (più ampio in AR),  il volume e 
flusso sanguigno sinovia/peri-sinovia. Non vi erano correlazioni tra parametri di flusso CEUS e dati 
clinici. 
Conclusione: Lo studio di immagini dinamico e automatizzato della sinovia (dynamic automated 
synovial imaging, DASI) costituisce un nuovo strumento per lo studio diretto della 
vascolarizzazione  in corso di artrite, che finora era solo possibile tramite la biopsia invasiva. DASI 
è altamente efficace nel discriminare l’AR dall’APs attraverso l’identificazione di un prototipo di 
vascolarizzazione distinto.   
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Introduction 
Arthritis is a modern socioeconomic emergency due to high prevalence -exceeding largely 
cardiovascular and pulmonary diseases- and potentially destructive process compromising 
irreversibly personal independence and charging institutional resources [1,2]. The prevalence of 
self-reported and doctor diagnosed arthritis is projected to increase in the US from actual 47.8 
million in 2005 to nearly 67 million by 2030 (25% of the adult population). And by 2030, 25 
million (9.3% of the adult population) are projected to report arthritis attributable activity 
limitations [3].  
 
1. Arthritis 
Arthritis is not a single disease - it is a term that covers over 100 medical conditions. Osteoarthritis 
(OA) is the most common form of arthritis and generally affects elderly patients. It is a degenerative 
disease of articular cartilage and subchondral bone exacerbated by other factors such as weight and 
trauma  and secondary synovial inflammation. 
Primary inflammation of synovial tissue (synovitis) is on the other hand a common final pathway in 
different inflammatory arthritides. Inflammatory arthritis may be caused by crystals (gouty 
arthritis), microbes (septic arthritis) or persistent immune reaction to microbial components 
(reactive arthritis).  Finally autoimmune pathway is on the base of a consistent number and forms of 
inflammatory arthritis. 
The 2 major and clinically most important primary inflammatory rheumatic diseases which affect 
small hand and feet joints are rheumatoid arthritis (RA) and psoriatic arthritis (PsA). The most 
important initial histopathological feature of RA is synovitis followed by chronic proliferative 
granulomatous pannus-tissue, which is associated with cartilage and bone destruction. Early 
inflammatory changes in RA also develop synchronously within the subchondral bone marrow. 
Enthesitis is the hallmark of seronegative spondyloarthritis (SpA) including PSA, and is often seen 
as one of the first radiological manifestations of the diseases. As a rule inflammation within the 
synovial joints, histologically similar to RA, is not so pronounced. Consequently destructive 
changes within the synovial joints are much less with the exception of PsA in which pronounced 
bone destruction may develop (arthritis mutilans). Considerable overlapping in clinical and 
morphological manifestation of RA and PsA may be present. For evaluation of hand and feet joints 
and surrounding soft tissue structures in RA and PsA different imaging modalities are used, which 
include conventional radiography (CR), ultrasound (US), radionuclide techniques and magnetic 
resonance imaging (MRI). Appreciation of typical combinations of various inflammatory features 
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within the small hand and feet joints and surrounding anatomic structures, as well as evaluation of 
their distribution, extension and intensity helps in making differential diagnosis. 
 
2. Normal anatomy and pathology of the synovial joints and 
the entheses  
Peripheral small hand and feet joints are anatomically complex diarthrodial (or synovial) joints, 
which enable great range of movements between the bones. Histologically they are composed of 4 
major structures, the synovium, the synovial fluid, the cartilage and the capsule with its ligaments. 
The hallmark of RA is synovitis. Since synovium is one of the most important structural 
components of the peripheral hand and feet joints abundant inflammatory changes within these 
joints are present in RA [4]. 
In SpA including PsA the hallmark of the diseases is enthesitis, an inflammatory enthesopathy at 
the insertions of the joint capsules, ligaments, tendons and aponeuroses [5]. Non-synovial 
fibrocartilaginous joints enable only limited range of movements and are mainly adapted for 
transmission of biomechanical forces. Entheses are fibrocartilaginous structures and are the sites 
exposed to repetitive biomechanical stressing. Excessive compressive and shearing forces can be 
transmitted for example from the muscle through the tendon to the bone. The anatomy and 
physiology of the entheses have not been studied extensively until recently. There are proves that 
the extracellular composition of the entheses includes a matrix synthesized by chondrocytes similar 
to those present in cartilage [6]. Concerning the synovial hand and feet joints entheses do not 
represent prominent anatomical structures and are limited to the small peripheral area, where the 
joint capsule inserts into the cortex of the bone shaft. Additional sites of entheseal insertions outside 
of the small joints are attachments of the collateral ligaments and paraarticular tendons. These are 
the sites where typical primary inflammatory changes occur at or near peripheral synovial joints in 
PsA. Synovial inflammation (synovitis) in PsA is supposed to be secondary to primary enthesitis.  
However overlapping of features typical for RA and those typical for SpA may be seen in both 
entities. The best example is PsA in which prominent synovial proliferation, morphologically 
indistinguishable from RA can be present within the hand and feet joints, the so-called simil-
rheumatoid PsA. 
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3. Rheumatoid Arthritis 
3.1. Impact of rheumatoid arthritis 
RA is a chronic autoimmune inflammatory disease affecting 1% of general population, and is 
characterized by erosive polyarthritis leading to joint destruction, disability and handicap. As 
consequence the majority of RA patients incur work loss, quality of life impairment and premature 
death. The accumulated economic burden resulting from RA is enormous. The total cost of RA in 
2006 was estimated at €45 billion in Europe and €42 billion in the United States, or close to €100 
billion in the countries covered [7]. The precise evaluation of the activity (inflammation) and 
severity (destruction) of RA is of paramount importance to assess disease prognosis and 
progression, and treatment efficacy. 
 
3.2. Pathogenesis of rheumatoid arthritis 
RA involves a complex interplay among genotype, environmental triggers, and chance [8]. Twin 
studies implicate genetic factors [9]. Genome analyses confirm that immune regulatory factors 
underlie the disease [10]. The long-established association with HLA DRB1 locus has been 
confirmed in seropositive patients [11]. Alleles that contain a common amino acid motif (QKRAA) 
in the HLA-DRB1 region, termed the shared epitope, confer particular susceptibility. These 
findings suggest that some predisposing T-cell repertoire selection, antigen presentation, or 
alteration in peptide affinity has a role in promoting autoreactive adaptive immune responses. Other 
possible explanations for the link between RA and the shared epitope include molecular mimicry of 
the shared epitope by microbial proteins, increased T-cell senescence induced by shared epitope–
containing HLA molecules, and a potential proinflammatory signaling function that is unrelated to 
the role of the shared epitope in antigen recognition [12,13]. 
Other immune regulator genes responsible for immune regulation such as nuclear factor κB (NF-
κB)- dependent signaling (REL, TNFAIP3, TRAF1, BLK, CCL21, FCGR2A, PADI4, PRDM1, 
TNFRSF14),  T-cell stimulation, activation, and functional differentiation (PTPN22, AFF3, CD28, 
CD40, CTLA4, IL2RA, IL-2, IL-21, PRKCQ, STAT4, TAGAP, CTLA4) are implicated in RA.  
Gene-environment interactions such as smoking and other forms of bronchial stress increase the 
risk of RA among persons with susceptibility HLA-DR4 alleles [14]. 
Environmental stressors such as smoke promote posttranslational modifications, through peptidyl 
arginine deiminase, type IV (PADI4), that result in quantitative or qualitative alteration in 
citrullination of mucosal proteins. Loss of tolerance to such neoepitopes elicits an autoimmune 
response and anti-cyclic citrullinated peptide (CCP) production. Infectious agents (Epstein-Barr 
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virus, Cytomegalovirus, Proteus species, Escherichia coli, Porphyromonas gingivalis in periodontal 
disease, oral and intestinal microbiota) and their products (heat-shock proteins) have long been 
linked with RA by molecular mimicry [15]. The formation of immune complexes during infection 
may trigger the induction of rheumatoid factor (RF), a high-affinity autoantibody against the Fc 
portion of immunoglobulin, which has long served as a diagnostic marker of  RA arthritis and is 
implicated in its pathogenesis. 
The greater risk of RA among women and the sometimes observed onset associated with adverse 
life events are explainable by links between the hypothalamic–pituitary–adrenal axis and cytokine 
production [16]. 
Traditionally, RA has been considered a Th-1 cell mediated disorder, and therefore is thought to be 
driven by a population of T cells producing inflammatory cytokines and chemokines [17].  
Antigen-activated CD4+ T cells stimulate monocytes, macrophages, and synovial fibroblasts to 
produce the cytokines IL-1, IL-6 and TNFα and to secrete matrix metalloproteinases through cell-
surface signaling as well as through the release of soluble mediators. IL-1, IL-6 and TNFα are the 
key cytokines that drive inflammation in RA. Activated CD4+ T cells also stimulate B cells, 
through cell surface contact and through the binding of CD40-CD40L, to produce 
immunoglobulins, including rheumatoid factor. The precise pathogenic role of RF is unknown, but 
it may involve the activation of complement through the formation of immune complexes. 
Activated CD4+ T cells express osteoprotegerin ligands that stimulate osteoclastogenesis. Activated 
macrophages, lymphocytes, and fibroblasts, as well as their products, can also stimulate 
angiogenesis, which explains the increased vascularity found in the synovium of patients with RA. 
Endothelial cells in the synovium are activated and express adhesion molecules that promote the 
recruitment of inflammatory cells into the joint. This process is enhanced by the release of 
chemokines, i.e. IL-8.  
Cell-cell contact is necessary both during the inductive phase of T cell activation and the effector 
phase, in which T cells indirectly mediate autoantibody production, joint inflammation and bone 
resorption [18]. In the inductive phase, TCR binding to antigen/MHC on antigen presenting cells 
(APCs) is a critical first step for T-cell activation. APCs are dendritic cells (DCs), activated 
macrophages, B cells and activated fibroblast-like synoviocytes (FLS). However, the nature of 
accessory signals received from APCs and of local cytokine environment during TCR stimulation 
determines the type of T-cell response and governs disease progression. Costimulation of T cells 
occurs trough ligation of CD28 with CD80/CD86 on APCs. Once activated, T cells upregulate 
expression of CTLA-4, an inhibitory receptor that has a higher affinity for CD80/CD86 than CD28, 
in order to modulate activation [19,20]. Inducible costimulator (ICOS) is highly expressed on 
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activated T cells found in patients with RA. The ligand for ICOS is expressed on professional APCs 
in synovial tissue [21,22]. The integrin lymphocyte function associated antigen (LFA)-1 (CD11a) is 
expressed on activated T cells and binds to intercellular adhesion molecule-1 (ICAM-1) found on 
the surface of many cell types. LFA-1 is important for lymphocyte homing into inflamed tissues 
through binding to blood vessel walls and subsequent extravasation. However, it also mediates 
cellular contact between T cells and APCs during antigen presentation [23].  
The effector functions of arthritogenic T cells are carried out in the synovial lining and intra-
articular space of the joints. Upon activation, T cells upregulate surface expression of CD40L, 
which stimulates APCs through interaction with CD40. In B cells, ligation of CD40 in combination 
with cytokine activation stimulates antibody synthesis and isotype switching. Ligation of CD40 also 
induces expression of costimulatory and adhesion molecules as well as production of 
proinflammatory cytokines, including IL-6, IL-8, MIP-1 (macrophage inflammatory protein-1), 
TNFα, and IL-12, by APCs [24,25]. These cytokines are known to participate in joint inflammation 
and act reciprocally on T cells to drive production of other cytokines and surface molecules 
involved in the effector phase of joint inflammation. Non-specifically cytokine activated T cells 
contribute to joint pathology. Another important effector function of synovial T cells involves 
upregulation of receptor activator of NF-κB ligand (RANKL) on the cell surface. T cells activate 
synovial monocytes to differentiate into osteoclasts, that mediate bone destruction.   
Recent evidence deriving from mouse models has questioned the role of Th1 cells in RA and 
identified a new Th subset, Th-17 cells. Th17 cells develop in the presence of tumor growth factor 
(TGF)-β, IL-6 and IL-23 and are characterized by production of the highly inflammatory cytokine 
IL-17. IL-17 induces expression of IL-1, IL-6, IL-8, prostaglandin E2 and granulocyte colony 
stimulating factor (CSF) and acts synergistically with TNFα. IL-17 receptor  is expressed 
ubiquitously. IL-17 directly and indirectly augments both inflammatory mediator production and 
joint destruction. IL-17 induces cartilage destruction and bone erosion by upregulation of RANKL. 
Many studies have built a strong case that IL-17 is a key suspect in the pathogenesis of RA: it is 
overexpressed in RA synovium and blood, it induces and synergizes with many inflammatory 
mediators important in joint pathology, and it is both necessary and sufficient for joint inflammation 
in animal models [26,27].  
T regulatory cells (Treg) have become a major focus of immunologic research in the past decade 
due to their participation in controlling effector T cell functions in vitro and to their potential for 
regulating autoimmune inflammatory responses in vivo [28]. Treg cells produce high levels of 
TGF-β and IL-10 [29]. Treg cells suppress immunological responses in multiple ways, which may 
involve negative signals produced by inhibitory surface molecules, cytotoxic killing, 
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downregulation of APC function, and induction of other regulatory cells. In RA, Treg cells have a 
defect in suppression of TNF-α and IFN-γ production from CD4+ T cells or monocytes, even 
though they can suppress the proliferation of effector T cells [30,31]. In other studies, it has been 
shown that effector T cells from peripheral blood of RA patients  were resistant to Treg mediated 
suppression [32]. Treg cells express TNFα receptor 2, and signaling through this receptor by TNF-α 
results in inhibition of suppressive function and decreased Foxp3 expression [33]. Treatment of RA 
patients with anti-TNF-α antibody leads to in vivo expansion of Treg cells, increased Foxp3 
expression, and restoration of cytokine suppressive function. Interestingly, healthy individuals 
respond to the arthritis-associated autoantigen, HCgp39 by producing IL-10 whereas patients with 
RA tend to produce proinflammatory cytokines. An important difference between healthy people 
and patients with RA is the ability to expand Treg cells specific for autoantigens [34]. 
NK cells subsets are widely distributed within the rheumatoid synovial membrane and could 
constitute a significant cytokine source. NK-cell activation by cytokines, including IL-12, IL-15, 
IL-18 leads to increased NK cell cytotoxic activity and release of cytokines, such as TNFα and 
IFNγ [35]. 
In addition to autoantibody production, and thereby immune-complex formation, the B cell lineage 
contributes to pathogenesis of RA. B cells produce cytokines and chemokines. B cell derived 
cytokines regulate the activation of follicular DCs and lymphoid neogenesis. The lymphocyte 
infiltrate in the synovium comprises various patterns of structural organization: cells can be 
diffusely distributed, loosely aggregated or form ordered structures that contain germinal centres 
(occurring in <20% of individuals affected with RA). Their presence predisposes to poorer 
outcome. DCs in synovial membranes that contain ectopic germinal centres produce high levels of 
the B cell survival factor APRIL (a proliferation inducing ligand). Macrophages and synovial 
fibroblasts in most synovial tissues can produce BAFF (B cell activating factor). Both stimulate 
proliferation and activation of B cells [36]. Cytokines and chemokines are directly implicated in this 
lymphocyte organization. CXCL13 and CCL21 promote the formation of synovial germinal centres. 
Germinal-centre formation in the synovium also requires the expression of lymphotoxin (LT)β, at 
least by B cells. The role of B cells in the joints as APCs is also important, as B-cell depletion 
prevents the formation of ectopic germinal centres and the optimal activation of T cells [37].  
Macrophages as member of innate immunity are considered an important source of synovial pro-
inflammatory cytokines. Activation of and subsequent cytokine production by macrophages (and 
synovial fibroblasts) in the synovium is likely to occur through pattern-recognition receptors 
(PRRs), such as Toll-like receptor (TLR)2, TLR3, TLR4 and TLR6, which recognize various 
microbial products, as well as putative endogenous ligands, including heatshock proteins and 
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fibronectin [38]. TLR expression is established in chronic disease and as such could serve not only 
to initiate but also to perpetuate disease. Cytokine expression in human synovial cultures is 
promoted through pathways that depend on the TLR signaling adaptor proteins MyD88 and TIRAP.  
Synovial monocytes can also be activated to produce cytokines by immune complexes through their 
cell-surface FcγRs. Finally, the synthesis of proteases, such as Mast cell tryptase and trypsin, by 
neutrophils and mast cells, regulates macrophage cytokine release by PAR2. 
Of the innumerable cytokines, that are released by synovial macrophages, TNFα is clearly of 
primary importance in the pathogenesis of RA [39]. TNFα induces leukocyte and endothelial-cell 
activation, synovial-fibroblast activation and survival, pain-receptor sensitization and angiogenesis, 
which together represent key pathological features of RA. Further essential macrophage derived 
cytokines are IL-1, IL-6, IL-15, IL-18 and IL-32. 
Other innate immune effector cells  implicated in RA pathogenesis are neutrophils present in high 
numbers in synovial fluid and synovial membrane. They synthesize a wide variety of cytokines, 
including TNFα, IL-1, IL-6, IL-15, IL-18 and BAFF, and therefore could support a range of 
pathological events. Neutrophils are activated by immune complexes, complement components and 
cytokines to release chemokines, prostaglandins, reactive oxygen and nitrogen intermediates and 
proteolytic enzymes, and therefore also probably contribute significantly to the general hypoxic and 
destructive milieu in inflamed joints [40]. Mast cells are similarly implicated at the crossroad of 
innate and adaptive synovial immunity. They are widely distributed in RA synovial tissue and 
express various proteases and pro-inflammatory cytokines [41].  
One important feature of rheumatoid synovitis is the relative expression deficiency of several 
regulatory cytokines, receptors and tissue enzyme inhibitors, thereby contributing to the imbalance 
between pro-inflammatory and anti-inflammatory actors. 
Inflammation and bone erosion are closely linked [42,43]. Normal physiological processes ensure a 
balance between bone formation and bone resorption to maintain skeletal homeostasis. This balance 
is perturbed in RA in favor of bone resorption. Bone resorption depends on osteoclasts. Mice with 
differentiation defects in the osteoclast lineage develop inflammatory arthritis that is not associated 
with bone erosion. In RA, osteoclasts at the interface between synovial tissue and articular bone 
induce bone resorption, which in turn permits invasion by cells of the synovial membrane and 
results in pannus formation. This process depends on the influx of osteoclasts precursors into 
inflamed synovial tissue and the differentiation of these cells into mature osteoclasts. Macrophage 
CSF (M-CSF) and RANKL are essential for the differentiation of osteoclasts from their precursor 
cells, and a lack of either molecule is sufficient to block osteoclast formation completely. M-CSF is 
expressed by synovial mesenchymal cells and to a lesser extent by T cells. TNF induces the 
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production of M-CSF by synovial fluid cells, as does IL-7, which promotes M-CSF production by 
Th1 cells. The action of M-CSF on monocytes is essential for osteoclastogenesis, but alone is 
insufficient to induce their final differentiation [44,45] 
RANKL, a member of the TNF superfamily, is expressed by mesenchymal cells, such as synovial 
fibroblasts, and activated synovial T cells. In rheumatoid synovial tissue, RANKL expression is up-
regulated and constitutes an important prerequisite for osteoclast differentiation. RANKL 
expression is regulated by inflammatory cytokines, such as TNFα, IL-1, IL-6 and IL-17, but is also 
influenced by non-cytokine inflammatory mediators such as prostaglandin E2. RANKL induces the 
final differentiation of osteoclasts and their bone resorbing activity. The interaction of RANKL with 
its receptor RANK is modulated by osteoprotegerin (OPG), a soluble decoy receptor, which is 
expressed by mesenchymal cells in the RA synovium [46]. In RA, an imbalance between OPG and 
RANKL expression promotes RANKL induced bone loss.  
Other cytokines in the inflammatory milieu also contribute to the destructive process. TNFα is a 
potent driver of osteoclast formation, acting either additively with RANKL or directly through 
TNFα receptor I. TNFα also mobilizes CD11b+ osteoclast precursors from the bone marrow [47]. 
IL-1β induces RANKL expression. Moreover, IL-1β is a key component of TNF-mediated 
osteoclastogenesis. IL-17 induces RANKL, TNFα and IL-1 expression by synovial fibroblasts to 
support osteoclast formation. Th17 cell inducing cytokines, including IL-23, TGFβ and IL-6, 
therefore, probably act on osteoclasts, too. RANKL expression is a key link in osteoimmunology, 
providing an explanation to why immune activation is linked to bone loss. 
Bone formation, which is the ‘physiological’ counterpart response to increased bone resorption is 
mediated by osteoblasts and is virtually absent in RA. TNFα inhibits osteoblast differentiation and 
function. TNFα upregulates secretory molecules, which acts as WNT protein inhibitors and blocks 
bone and cartilage formation [48].  
Synovial fibroblasts concur in joint damage by producing inflammatory signals. In rheumatoid 
joints, synovial fibroblasts exhibit anchorage independent growth, loss of contact inhibition and 
increased proliferation, and play a central role in chronic synovitis and pannus formation, which 
depends from cadherin-11 [49]. Synovial hyperplasia is induced by exposure to cytokines, such as 
fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and TGFβ, together with the 
induction of expression of oncogenes, such as RAS and MYC, and survival proteins, such as heat-
shock protein 70 (HSP70). Matrix degrading enzymes are produced by synovial fibroblasts, 
neutrophils and mast cells, which are closely located to articular cartilage, and chondrocytes 
themselves. Such enzymes released constitute enzymatic milieu responsible for the local migratory 
activity of pannus and articular cartilage invasion [50]. Synovial fibroblasts promote further T-cell 
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and B-cell migration, activation and survival. In turn, B cells promote synovial-fibroblast activation 
through IgG binding to FcγR on synovial fibroblasts. Together these data indicate a central role for 
synovial fibroblasts in integrating the inflammatory and destructive phases of inflammatory 
arthritis. 
The production of vascular endothelial growth factor (VEGF), FGF, oncostatin M and IL-18 by 
synovial fibroblasts promotes angiogenesis typical of the rheumatoid synovium. This profuse 
angiogenetic activity is in turn a prerequisite for inflammation and destruction. Inhibition of 
angiogenesis suppresses synovitis [51]. 
 
3.3. Clinics of rheumatoid arthritis 
Rheumatoid arthritis is characterized by synovial inflammation and hyperplasia (“swelling”), 
autoantibody production (RF and anti-CCP), cartilage and bone destruction (“deformity”), and 
systemic features, including cardiovascular, pulmonary, psychological, and skeletal disorders. 
The typical case of RA begins insidiously, with the slow development of signs and symptoms over 
weeks to months. Often the patient first notices stiffness in one or more joints, usually accompanied 
by pain on movement and by tenderness in the joint. The number of joints involved is highly 
variable, but almost always the process is eventually polyarticular, involving five or more joints, 
especially small joints of hands and feet. RA is an additive polyarthritis, with the sequential 
addition of involved joints. Occasionally, patients experience an explosive polyarticular onset. 
Other not as usual manifestations are polymyalgia-like onset, systemic onset and oligo-/ 
monoarticular forms. The joints involved most often are the proximal interphalangeal (PIP) and 
metacarpophalangeal (MCP) joints of the hands, the wrists (particularly at the ulnar-styloid 
articulation), shoulders, elbows, knees, ankles, and metatarsophalangeal (MTP) joints. The distal 
interphalangeal (DIP) joints are generally spared as the spine except the atlanto-axial articulation is. 
Morning stiffness, persisting more than one hour but often lasting several hours, may be a feature of 
any inflammatory arthritis but is especially characteristic of RA. Its duration is a useful gauge of the 
inflammatory activity of the disease. Symmetric joint swelling, although not invariable, is 
characteristic of RA. Fusiform swelling of the PIP joints of the hands is a common early finding. 
MCP, wrists, elbows, knees, ankles and MTP are other joints commonly affected where swelling is 
easily detected. Redness of affected joints is not a prominent feature of RA. Occasionally inflamed 
joints will feel warm to the touch. Pain on passive motion is the most sensitive test for joint 
inflammation. Inflammation may limit the range of motion of the joint. As the pathology progresses 
the inflammatory activity leads to tendon displacement or rupturing and to erosions with destruction 
of the joint surface, which impairs range of movement and leads to deformity and joint ankylosis. 
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The fingers may suffer from almost any deformity depending on which joints are most involved 
Most characteristic deformities are ulnar deviation, “Z”-thumb, boutonniere and swan neck  
deformity. Nonspecific systemic symptoms primarily fatigue, malaise, anorexia, weight loss and 
depression, may concur or precede other symptoms of the disease by weeks to months. Patients 
complain of severe fatigue 4 to 6 hours after wakening. Fever occasionally occurs and is almost 
always low grade [52]. 
Extra-articular manifestations other than anemia are clinically evident in about 15-25% of 
individuals with RA [53]. The rheumatoid nodule, which is often subcutaneous, is the skin feature 
most characteristic of RA. The initial pathologic process in nodule formation is unknown but may 
be essentially the same as the synovitis, since similar structural features occur in both. The nodule 
has a central area of fibrinoid necrosis that may be fissured and which corresponds to the fibrin-rich 
necrotic material found in and around an affected synovial space. Surrounding the necrosis is a 
layer of palisading macrophages and fibroblasts, corresponding to the intimal layer in synovium and 
a cuff of connective tissue containing clusters of lymphocytes and plasma cells, corresponding to 
the subintimal zone in synovitis. The typical rheumatoid nodule may be a few millimeters to a few 
centimeters in diameter and is usually found over bony prominences, such as the olecranon, the 
calcaneal tuberosity, the MCP joints, or other areas that sustain repeated mechanical stress. Nodules 
present in 20% of patients are associated with a positive RF titer and severe erosive arthritis. Rarely, 
these can occur in internal organs or at diverse sites on the body. Vasculitic skin manifestations 
include nailfold microinfarcts, livedo reticularis, purpura, ischemia, ulcers or erythema nodosum. 
Palmar erythema and diffuse thinning and skin fragility may be present. 
There are several pulmonary manifestations of RA, including pleurisy with or without effusion, 
intrapulmonary nodules, rheumatoid pneumoconiosis (Caplan's syndrome), diffuse interstitial 
fibrosis, and rarely BOOP, pneumothorax and pulmonary hypertension. Cardiac manifestations are 
pericarditis as the most common, further disturbances of atrioventricular conduction, endocarditis 
with resulting valvulopathies and rarely myocarditis.   
Renal amyloidosis can occur as a consequence of chronic inflammation. RA may affect the kidney 
directly through vasculopathy or mesangial glomerulonephritis, but this is less well documented. 
Hepatic involvement in RA is essentially asymptomatic. Activation and cytokine production by 
Kupffer cells can be so marked that the increase in hepatocyte activity may result in palpable 
nodular hyperplasia of the liver.  Intestinal vasculitis is a very rare manifestation of RA. 
Keratoconjunctivitis sicca is the most common ocular manifestation of RA due to secondary 
Sjögren syndrome. When severe, dryness of the cornea can lead to keratitis and loss of vision. 
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Episcleritis occurs occasionally and is manifested by mild pain and intense redness of the affected 
eye. Scleritis and scleromalacia are rare but may result in perforation, infection and visual loss.  
Peripheral neuropathy and mononeuritis multiplex are due to rheumatoid vasculitis. The most 
common problem is carpal tunnel syndrome caused by compression of the median nerve by 
swelling around the wrist. Atlanto-axial subluxation can occur, owing to erosion of the odontoid 
process and/or rupture of transverse ligament. Clumsiness is initially experienced, but without due 
care this can progress to quadriplegia.  
Felty's syndrome is nowadays a rare complication of RA and is characterized by splenomegaly, and 
leukopenia - predominantly granulocytopenia. 
Local osteoporosis occurs in RA around inflamed joints. It is postulated to be caused by 
inflammatory cytokines. General osteoporosis results from immobility, systemic cytokine effects, 
local cytokine release in bone marrow and corticosteroid therapy.  
Atherosclerosis is accelerated in RA by effect of systemic inflammation. The major cause of 
mortality in RA is cardio- and cerebrovascular disease. The incidence correlates with C-reactive 
protein (CRP) levels [54]. 
RA patients with active disease are at higher risk to develop non-Hodgkin lymphoma (NHL) of B 
cells and bronchial carcinoma. 
 
3.4. Diagnosis of rheumatoid arthritis 
Despite the typical clinical finding of polyarthritis of the small hand and foot joints bloods exams 
can reveal increase of CRP, erythrocyte sedimentation rate (ESR) and other acute phase proteins. 
Normocytic normochromic anemia may be present due to inflammation driven iron sequestration in 
reticuloendothelial system, hepcidin induced reduction of intestinal iron absorption due to inhibition 
of  blood stem cells by inflammatory cytokines. Leukocytosis and thrombocytosis may occur. 
Immunological alterations which may be present include the positivity for RF, anti-citrullinated 
protein antibodies (ACPA), anti-nuclear antibodies (ANA) and hypergammaglobulinemia. The 
most common tests for ACPA are the anti-CCP and the antibodies against mutated citrullinated 
Vimentin [55]. 
Diagnosis of RA is established following the American College of Rheumatology (ACR) 
classification criteria of 1987 or newer ACR/European League against Rheumatism (EULAR) 
classification criteria of 2010 [56,57]. The latter criteria promote earlier diagnosis and start of 
therapy. In cases not completely fulfilling criteria evaluation of radiographic erosions may ensure 
diagnosis of RA [58]. 
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ACR criteria 1987 for the classification of RA:  
 Morning stiffness of >1 hour for at least 6 weeks  
 Arthritis and soft-tissue swelling of 3 joint groups, present for at least 6 weeks  
 Arthritis of hand joints (MCP, PIP, wrist), present for at least 6 weeks  
 Symmetric arthritis, present for at least 6 weeks  
 Rheumatoid nodules  
 Positivity of RF/anti-CCP 
 Radiological changes as joint erosions and/or periarticular osteoporosis 
At least four criteria have to be met for classification as RA. 
  
ACR/EULAR criteria 2010 for the classification of RA: 
A Joint involvement       Score 
 1 large joint       0 
 2-10 large joints      1 
 1-3 small joints     2 
 4-10 small joints     3 
 >10 joints (at least 1 small joint)   5 
B Serology 
 Negative APCA and RF    0 
 Low-positive APCA or RF    1 
 High-positive APCA or RF    2 
C Acute phase reactants 
 Normal CRP and ESR    0 
 Abnormal CRP or ESR    1  
D Duration of symptoms 
 < 6 weeks      0 
 => 6 weeks      1 
At least 6 points have to be met for classification as RA. 
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3.5. Outcome of rheumatoid arthritis 
During the mid-1980s, it became apparent that most patients seen in rheumatology clinics with 
symptoms and signs of RA for longer than 3–6 months rarely experienced spontaneous remission, 
and most had a progressive disease [59,60]. It was recognized that short-term drug efficacy was not 
translated into long-term effectiveness as most patients seen in the 1980s were found to experience 
radiographic progression, severe functional declines, work disability, and premature mortality, and 
many patients required joint surgery [61-64]. The long-term severity of RA was recognized in 
longitudinal studies of clinical cohorts that indicated continuous radiographic progression over 
follow-ups in excess of 20 years. These reports led to calls for early and aggressive use of disease-
modifying anti-rheumatic drugs (DMARDs) including aggressive strategies to prevent severe long-
term outcomes of RA [65-67].  
Joint damage occurs early in the course of RA. Radiographs are a suitable outcome measure in 
patients with RA. They reflect the history of the joint pathology and provide a permanent record 
necessary for serial evaluation of the disease. The extent of damage in the joints of the hands and 
wrists gives a good overall indication of both the extent of overall joint damage at a given time and 
the rate of progression of damage. Several authors have shown in cohort studies of patients with 
early RA that MTP are eroded earlier and show more damage [68]. 30% of patients have 
radiographic evidence of bony erosions at the time of diagnosis, and this proportion increases to 
60% by two and to 70% by 3 years despite conventional treatment [69,70]. Patients with more than 
one erosion, when first seen, are more likely to have severe radiographic damage at 3 years. 
Positivity for RF and/or ACPA, elevated erythrocyte sedimentation rate (ESR), non-response to 
therapy and delayed treatment influence further negatively radiographic progression. Unfortunately, 
bony erosions and deformities are largely irreversible and represent a cumulative process of 
inflammation over time [71]. Initiation of therapy with DMARDs within three months after the 
diagnosis of RA is crucial; a delay of as little as three months in the introduction of these 
medications results in substantially more radiographic damage at five years. Therefore, early 
diagnosis, although challenging, is critical [72-76]. It is commonplace for patients to have erosions 
when they are first seen. Patients with very early RA, who were seen within 3 months of their first 
symptoms, had erosions present at their first assessment in 13% of cases, and after 12 months of 
follow-up, this had increased to 28% [77]. The call for prompt therapeutic intervention even earlier 
to ameliorate patients’ response and outcome has led to the recommendation to investigate patients 
with polyarthritis lasting for more than 6 weeks for the suspect of RA. 
RA has a major impact in many areas of individuals’ lives, not just those traditionally considered to 
be the domain of medical intervention. The most important problems are persistent pain and loss of 
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function, that result in disability and impaired quality of life. Pain is a dominant concern of patients 
with RA, and its persistence is a highly negative consequence of disease. Pain scores correlate with 
patients’ global assessment of disease and morning stiffness far more than from radiographic or 
other clinical variables such as the number of tender and swollen joints. Clinical experience 
suggests that at least part of the pain of early RA appears to be related to depression. However, 
patients may also suffer other symptoms, such as fatigue, and adverse effects from therapy.  Fatigue 
measured is a dominant factor in determining the quality of life and psychosocial aspects of daily 
functioning. 
Loss of functional capacity is a major determinant of morbidity and a predictor of mortality of 
patients with RA [78-82]. In term of disability the long-term prognosis of RA is poor: 80% of 
affected patients are disabled after 20 years [83]. Disability in RA is measured using disease-
specific measures, especially the Health Assessment Questionnaire (HAQ). RA patients have 
considerable disability before they start treatment. Therapy with symptomatic agents and DMARDs 
initially improves synovitis and hence associated disability. The reversible component is that related 
to joint pain, stiffness, and swelling due to inflammation, or associated symptoms such as 
depression. Thereafter the disability rises again slowly as joint damage and other disease 
manifestations progress in a manner that no longer respond to therapy. Indeed, in early RA, 
disability, measured by HAQ is correlated with disease activity, whereas correlation with joint 
damage increases with time. Responsiveness in HAQ scores is inversely associated with mean 
disease duration in RA. Thus, HAQ comprises mainly a reversible activity related component and 
an irreversible one due to joint damage. Disease activity can be best assessed using composite 
indices; joint damage is usually measured by the Total Sharp Score (TSS) and its derivatives. Both 
the TSS and the change in TSS (progression rate) are significant determinants of the HAQ score. It 
has been estimated that 0,1 HAQ points correspond to 10 TSS points [84]. However, disability is 
also related to other factors, like age, psychosocial aspects or comorbidities. Physical disability is 
worsening with increasing level of comorbidity, irrespective of disease activity [85-87]. 
RA has many consequences, not only for the individual but also for their friends and family and for 
the whole of society. The impact of RA on society includes high medical and indirect costs, reduced 
ability to work, and the need for additional help and support from family and friends. Particular 
concern has raised about work disability. It has been estimated that about one-third of people with 
RA leave employment prematurely, and work disability involves patients with early RA as well as 
those with longstanding disease. Work disability often starts soon after diagnosis and subsequently 
continues at a steady rate. Estimates of the prevalence of work disability among people with RA are 
as high as 62%, with permanent disability ranging from 31 to 42% [88].  
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In addition, RA patients have approximately twice the mortality rate of the general population, with  
cardio- and cerebrovascular diseases accounting for the excess of death. RA patients have a 2- to 3-
fold increased risk of myocardial infarction, a 2-fold increased risk of congestive heart failure, a 2-
fold increased risk of sudden death, and a 1.7-fold increased risk of strokes. Serious infections 
(leading to hospital admission, intravenous antibiotics or death) are major contributor to increased 
mortality, with the risk estimated to be two-to-three times that of the general population. Further 
contributors to increased morbidity and mortality are gastrointestinal, pulmonary and renal disease 
due to RA or its medication and excess in malignancy incidence especially of lymphoma and 
bronchial carcinoma, whom are correlated to disease activity [89]. In summary, life expectancy of 
RA patients is reduced by an average of 3 to 18 years [90]. 
 
3.6. Distinguishing features of rheumatoid arthritis 
 Th1 immune reaction associated with HLA DRB1 and driven by CD4+ T-cells 
 Woman are more often affected. 
 There is a predilection for the synovial joints, at the beginning typically of MCP, MTP and 
PIP joints of the hands and the feet with possible affection of all synovial joints in chronic 
disease. As a rule DIP are not affected. 
 Inflammatory changes are multifocal and symmetrical with centripetal progression during 
the course of disease. 
 Synovitis and/or Tenosynovitis can be assessed clinically and by CR, computer tomography, 
bone scintigraphy, PET, US, MRI. 
 From the beginning of the disease destructive, “minus” changes predominate – juxtaarticular 
demineralization, cartilage and bone erosions. Therefore RA in contrary to peripheral PsA 
is called “minus” or “atrophic” arthritis. 
 Productive changes – periostosis, osteosclerosis, bone ankylosis, enthesiophytes (typical for 
SpA) are absent or modest. 
 Affection of the fibrocartilaginous joint is rare and modest. 
 RF and APCA are positive. Anemia may be present. CRP and ESR are very often elevated. 
 Rheumatic nodules are present in seropositive from. Systemic and organ involvement is 
possible. 
 The most important initial histopathological feature of RA is synovitis followed by chronic 
proliferative granulomatous pannus-tissue, which is associated with cartilage and bone 
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destruction. Early inflammatory changes in RA also develop synchronously within the 
subchondral bone marrow. 
 
4. Psoriatic Arthritis 
4.1. Impact of psoriatic arthritis 
PsA has been defined as an inflammatory arthritis, usually seronegative, associated with psoriasis 
(PsO). It emerged as a clinical entity separate from RA following the discovery of the RF in 1948  
[91]. Prevalence of PsO has been estimated between 2% and 3%, the estimated prevalence of 
inflammatory arthritis among patients with psoriasis has varied widely from 6% to 42%. A recent 
study from Sweden suggests that PsA occurs in 30% of patients with psoriasis [92]. Similarly a 
study of patients attending a psoriasis clinic identified 31% as having PsA. The prevalence of PsA 
in the general population should be close to 1%.  PsA occurs just as frequently in both sexes. The 
impact of the disease in patients with PsA appears to be similar to that of patients with RA. 
 
4.2. Pathogenesis of psoriatic arthritis 
Compared with most other rheumatic diseases, heredity plays a particularly strong role in the 
development of PsA. About 15% of the relatives of an index patient with PsA will also have PsA, 
and an additional 30% to 45% will have PsO. Accordingly, the presence of either PsO or PsA in a 
family member of a patient suspected of having PsA provides support for the diagnosis. 
Identification of the genes responsible for this high degree of familial aggregation remains an 
ongoing process but, among the identified genes, the HLA genes in the MHC are of primary 
importance in the development of PsA. The patterns of inheritance of PsO and PsA are those of a 
genetically complex multigenic disease [93]. 
In contrast to most other autoimmune diseases in which susceptibility is specified by HLA-DR or 
other class II MHC genes, in PsA it is the class I genes, notably alleles at the HLA-B and HLA-C 
loci, that are involved [94]. These include the HLA-C allele Cw*0602, which is the major 
determinant of susceptibility to PsO, and the HLA-B alleles B*27 and B*39, and possibly some 
additional alleles HLA-DRB1*04 alleles encoding the shared epitope are strongly associated with 
susceptibility to RA, but not with PsA. Furthermore, they showed that HLA-Cw*06 and HLA-
DRB1*07 were indeed associated with patients with PsA having type I (onset before age 40 years) 
but not type II PsO (onset after age 40 years). Ongoing analyses indicate that these several MHC 
alleles operate independently in specifying the disease phenotype of PsA. This suggests that there 
could be two genetic pathways to PsA. One is through the function of the HLA-B alleles B*27 and 
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B*39, and another is through the function of haplotypes containing the HLA-C allele Cw* 0602 
(Psors1). Evidence is emerging that these two forms of PsA that share the PsO phenotype are subtly 
different. It appears that the Cw*0602 alleles confer a phenotype with more severe skin disease and, 
on average, a long interval (≥10 years) between the appearance of PsO and the development of the 
musculoskeletal features of PsA. In those with B*27 or B*39, the musculoskeletal component 
appears more synchronously with the cutaneous component, and PsA is more likely than in the 
presence of Cw*0602.  
The presence of susceptibility genes in an individual defines the first preclinical stage of the 
development of PsA. The explanation for the association of the HLA alleles B*27 and B*39, and 
Cw*0602 with PsA susceptibility is that the molecules encoded by these alleles recognize 
selfpeptides derived from proteins found in entheseal and synovial sites. T-cell clones specific for 
these self-peptides would be inappropriately activated, perhaps by dendritic cells, and the activated 
state perpetuated by the continual supply of self-peptides. The T-cell repertoire that is developed on 
the individual’s self-peptides and self-MHC is poised for autoreactivity, but remains quiescent until 
triggered. An overbalance of stimulatory signals by infections, smoke or trauma may be responsible 
for engagement of the CD8+ T cells through NK receptors or other  innate immune signal receptors. 
Once triggered the immune process results in the development of the two main features of PsA: the 
inflammatory infiltrate of CD8+ T-cells and accessory cells into the entheses and synovium, and the 
response of the synovial and entheseal tissues to the products and consequences of the inflammatory 
infiltrate.  
 
4.3. Clinics of psoriatic arthritis 
Wright identified five clinical patterns among patients with PsA: distal predominant pattern (5%), 
oligoarticular asymmetrical (70%), polyarticular RA-like (15%), spondylitis (5%), and arthritis 
mutilans (5%); the majority of PsA patients having oligoarthritis [95]. These patterns are likely 
more relevant at disease onset as patterns  likely change and patients may tend to develop the 
polyarticular pattern over time. 
The specific clinical features include the common involvement of DIP joints in PsA. The joint 
distribution tends to occur in a ray pattern in PsA so that all the joints of a single digit are more 
likely to get affected than the same joints on both sides, which is typical of RA. This may explain 
the tendency to asymmetry that occurs even in the polyarticular disease in PsA. The concomitant 
extensive tendon involvement rises the picture of sausage digits.  The degree of erythema over 
affected joints and lower level of tenderness are also typical features of PsA. The deformities that 
may result from PsA lead to shortening of digits because of severe joint or bone lysis, with the most 
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severe form being the telescoping of digits. Bony fusion of joints may also occur in PsA. These 
changes are seen in radiographs as the classic pencil in cup and ankylosis, respectively. Marginal 
erosions alternated with areas of bone proliferation and periostal appositions are also typical 
radiographic aspects [96]. 
Typical feature of PsA is the involvement of entheses and of axial skeleton (sacroileitis and 
spondylitis, fusion of sacroiliac joints and syndesmophytes), often in an asymmetric manner. 
Therefore PsA is classified with SpA. Spondylitis is present in up to 40% of patients, extra-articular 
features may occur: mucous membrane lesions, uveitis, urethritis, diarrhea, aortic root dilatation and 
association with HLA-B27 [97]. 
Although by definition, all patients with PsA must have psoriasis, the arthritis may precede or occur 
without PsO. Nail lesions occur in about 40–45% of patients with PsO uncomplicated by arthritis 
and about 87% of patients with PsA.  
Rheumatoid nodules are absent. RF is detected in only about 13% of patients with PsA. Major 
organ involvement is rare, and metabolic syndrome often associated. 
 
4.4. Diagnosis of psoriatic arthritis 
Diagnosis of PsA is established by CASPAR (ClASsification criteria for Psoriatic Arthritis) criteria 
and other criteria systems [98,99] 
 
CASPAR criteria: A patient must have inflammatory articular disease (joint, spine, or entheseal) 
with ≥3 points based on points assigned to each feature 
Criteria       Score 
Presence of psoriasis      2 
Personal or family history of psoriasis   1 
Dactylitis       1 
Juxtaarticular new bone formation    1 
Rheumatoid factor negativity    1 
Nail dystrophy      1 
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4.5. Outcome of psoriatic arthritis 
PsA is suggested to be less severe than that seen in RA. However, about 20% of the patients 
develop a very destructive disabling form of arthritis. A recent study of early onset PsA showed that 
within two years of onset, 47% of patients demonstrated at least one erosion.36 This rate is in 
keeping with previous observations that 67% of patients seen in PsA clinics had evidence of erosive 
disease [100]. Identified predictors for future radiographic damage include polyarthritis, nail 
disease, high use of steroids, female gender, established damage, HLA-B27 in the presence of 
HLA-DR7, HLA-B39 and HLADQw3 in the absence of HLA-DR7 [101]. In a study each actively 
inflamed joint (tender and/or swollen) resulted in a 4% risk of increased damage at the next visit. 
Thus, if a patient had 20 actively inflamed joints, there was an 80% chance of progression of 
damage from the beginning to the end of the study [102]. A low ESR and HLA-B22 were noted to 
be protective. 
One study showed patients with PsA had similar radiological damage as patients with RA, 
suggesting that the disease may be just as destructive radiologically. Another study suggested that 
the radiological changes are not quite as severe [103,104]. 
Patients with PsA have reduced quality of life and functional capacity compared with PsO patients 
or healthy controls. Thus, the severity of the disease has an impact on the functional status and 
quality of life of patients with PsA. The Medical Outcome Survey Short Form 36 has also been 
validated in PsA and has shown significant differences between patients with PsA and the general 
population. The severity of PsA is reflected also in increased mortality. Patients with PsA are at an 
increased risk for death with a mortality ratio of 1.62. The causes of death are similar to those noted 
in the general population, with cardiovascular causes being the commonest. The risk for premature 
death is related to previously active and severe disease, the level of medication, the presence of 
erosive disease, and a high sedimentation rate at presentation to clinic [104]. 
 
4.6. Distinguishing features of psoriatic arthritis 
 Th2 or Th0 immune reaction mediated by CD8+ T-cells associated with MHC I molecules  
 PsA occurs just as frequently in both sexes. 
 There is a predilection for fibrocartilaginous articulations (entheses, sacroiliac joints, 
discovertebral junction etc.)  
 Inflammatory changes are frequently distally and asymmetrical in distribution. 
 Enthesitis is the hallmark of PsA and SpA and the first radiological manifestations of the 
diseases. It can be detected by assessed clinically and by CR, computer tomography, bone 
scintigraphy, PET, US, MRI. 
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 From an early stage of the diseases PsA is characterized by bone productive changes: 
periosteal apposition, osteosclerosis, bony ankylosis, ossification of ligaments, tendons, 
aponeuroses, articular capsules. Therefore in contrary to RA –which is termed “minus” or 
“atrophic” arthritis- seronegative peripheral arthritis represents so-called “plus” arthritis. 
Productive changes dominate the end stage of the disease which is characterized by 
metaplastic transition of the fibrous tissue to bone with pronounced joint ankylosis. 
 An important diagnostic feature of PsA and SpA is simultaneous existence of all reactive 
bone - joint capabilities. From the beginning of the disease there is a combination of 
destructive changes (such as juxtaarticular demineralization and erosions) as well as 
productive signs (which include periosteal apposition, osteosclerosis and bone ankylosis).  
 Specific antibodies are not known. CRP and ESR are often within normal range. 
 PsO, nail dystrophy and other SpA features are often present. Organ involvement is rare. 
 Inflammation within the synovial joints, histologically similar to RA, is not so pronounced. 
Consequently destructive changes within the synovial joints are much less with the 
exception of PsA in which pronounced bone destruction may develop (arthritis mutilans). 
 
5. Histopathology in Arthritis 
Synovitis is a major characteristic of chronic inflammatory joint diseases of autoimmune origin, 
such as RA and SpA. It can also occur as a secondary inflammatory symptom in OA, which is 
primarily induced by biomechanical stress on cartilage and subchondral bone.  
Studies in RA indicate that the synovial membrane has a dominant role in the joint inflammation 
and destruction, as suggested by the changes in synovial histology: (a) thickening of the synovial 
lining layer, as a result of infiltration by CD68+ cells and both proliferation and reduced apoptosis 
of type B synoviocytes; (b) neovascularization of the sublining layer; (c) infiltration of the sublining 
with T and B lymphocytes, plasma cells, and macrophages; and (d) alteration of the adhesion 
molecule expression, including the expression of αV integrins which may have a role in both 
neovascularization and pannus formation [105]. 
These observations suggest that the synovial membrane is both the primary site of inflammation, 
triggered by autoreactive T cells and macrophages, and the main effector organ, as the hyperplastic 
“aggressive” pannus leads to cartilage and bone erosion. The normal synovium contains 
mesenchymal-derived FLSs and resident macrophages. In RA, the membrane lining is expanded, 
and FLSs assume a semiautonomous phenotype characterized by anchorage independence, loss of 
contact inhibition, and the expression of high levels of disease relevant cytokines and chemokines, 
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adhesion molecules, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases 
(TIMPs). FLSs thereby contribute directly to local cartilage destruction and the chronicity of 
synovial inflammation, and they promote a permissive microenvironment that sustains T-cell and 
B-cell survival and adaptive immune organization [106]. The molecular mechanisms that sustain 
synovial hyperplasia are incompletely understood. The increased proliferative capacity of FLSs is 
not explanatory. A more likely possibility is altered resistance to apoptosis, which is mediated by 
diverse pathways, including mutations of the tumor-suppressor gene p53; expression of stress 
proteins (e.g., heat-shock protein 70), which foster the survival of FLSs; and modulation of the 
function of the endoplasmatic reticulum by synoviolin, an E3 ubiquitin ligase that regulates the 
balance of cell proliferation and apoptosis [107,108]. Synoviolin negatively regulates p53 
expression and its biologic functions. In addition, cytokine-induced activation of the NF-κB 
pathway in FLSs favors survival after ligation of TNF-α receptor. Methylation and acetylation of 
cell-cycle regulatory genes and expression of microRNAs may be critical factors [109]. Synovial 
hyperplasia could also reflect increased influx of mesenchymal cells. In a mouse model of arthritis 
with severe combined immunodeficiency, FLSs were shown to migrate and thereby promote 
articular involvement [110]. A crucial advance has been the elucidation of the molecular pathways 
that sustain integral membrane structure in rheumatoid arthritis. Cadherin-11 and β-catenin 
mediate FLS-homotypic interactions that are essential for membrane formation and for subsequent 
inflammation [111]. 
Inflammatory synovitis is characterized by increase in volume of the synovium due to hypertrophy 
and multiplying of the synoviocytes, by influx of inflammatory cells, such as the lymphocytes, 
plasma cells and macrophages into the synovium, by edema and fibrosis of the synovial matrix and 
by increased vascularity. A hyperplastic synovium is the major contributor to cartilage damage in 
RA. Loss of the normally protective effects of synovium (reduced expression of lubricin) alter the 
protein-binding characteristics of the cartilage surface, promoting FLS adhesion and invasion. FLS 
synthesis of MMPs (particularly MMP-1, 3, 8, 13, 14, and 16) promotes disassembly of the type II 
collagen network and collagenous cartilage matrix, a process that alters glycosaminoglycan content 
and water retention and leads directly to biomechanical dysfunction. Other matrix enzymes (e.g., 
ADAMTS 5) degrade aggrecan and thus further diminish cartilage integrity. Endogenous enzyme 
inhibitors, such as TIMPs, fail to reverse this destructive cascade [112]. Moreover, articular 
cartilage itself has limited regenerative potential. During inflammation (IL-1 and IL-17A) 
chondrocytes undergo progressive deprivation and apoptosis. These processes ultimately lead to the 
destruction of the surface cartilage and the radiographic appearance of joint-space narrowing. Bone 
erosion occurs rapidly (affecting 80% of patients within 1 year after diagnosis). Synovial cytokines, 
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particularly M-CSF and RANKL promote osteoclast differentiation and invasion of the periosteal 
surface adjacent to articular cartilage. TNFα and IL-1, 6 and 17 amplify osteoclast differentiation 
and activation. Osteoclasts have the acidic enzymatic machinery necessary to destroy mineralized 
tissues, including mineralized cartilage and subchondral bone [113,114] Resorption pits are filled 
by inflammatory tissue. Breach of cortical bone permits synovial access to the bone marrow, which 
causes inflammation of the bone, in which T-cell and B-cell aggregates gradually replace marrow 
fat.  It is established that inflammation can also start directly in bone marrow and precede erosions 
[115]. Eroded periarticular bone shows little evidence of repair in RA, unlike bone in other 
inflammatory arthropathies. Cytokine-induced mediators (DKK-1) inhibit WNT system and 
therefore the differentiation of mesenchymal precursors into chondroblasts and osteoblasts [116]. 
Synovial histopathology in PsA is generally characterized by neovascularization, and inflammatory 
infiltration with predominantly mononuclear cells (T lymphocytes, B lymphocytes and plasma cells, 
and macrophages), although PMCs can also be detected. Mild to moderate synovial lining 
hyperplasia is observed in a considerable percentage of cases [117]. 
The macro- and microscopic features of synovitis seem to be similar in different arthropathies, and 
have been defined as nonspecific synovitis [118]. However, some studies compared peripheral 
synovitis and histopathological characteristics of PsA with those of ankylosing spondylitis 
(AS)/undifferentiated SpA and RA, and compared the synovium of oligoarticular versus 
polyarticular PsA [105,119]. The histological analysis included examination of the lining layer 
thickness, vascularity, cellular infiltration, lymphoid aggregates, plasma cells, neutrophils, T cell 
subsets, E-selectin, ICAM-1, vascular cell adhesion molecule-1, S100A12, intracellular citrullinated 
proteins and MHC–human cartilage (HC) gp39 peptide. complexes.  
Comparing SpA (PsA, AS and SpA) with RA, vascularization, neutrophils and CD163+ 
macrophage counts were greater in SpA, whereas lining layer thickness and the number of CD83+ 
dendritic cells were greater in RA. At microscopic level there was further an increased maximal 
lining thickness in late RA compared to early RA, whereas all other parameters were the same in 
both disease stages. On synovial fibroblasts in RA compared to SpA a strongly significant decrease 
of αVα3 in the synovial lining layer and increase of αVα5 in the sublining layer is found. As 
engagement of αV integrins regulates proliferation, migration, and collagenase expression of a 
variety of cell types, this differential integrin expression may have an important role in the 
aggressive growth of the synovial pannus in RA.  
CD3+, CD4+ and CD20+ lymphocytes and plasma cells were overrepresented in RA compared 
with SpA, the CD4/CD8 ratio higher in RA. Th1 cytokine pattern of expression is characteristic of 
RA whereas in SpA, a Th2 or Th0 cytokine pattern is more frequent. For both diseases synovial 
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lining, vascularization degree and cellular infiltrations were dependent from local disease activity 
and effusion. CRP and ESR correlated only weakly with local inflammation in RA, whereas no 
correlation was found with CRP and ESR in PSA/SpA and with other disease activity parameters 
such as counts of swollen and tender joints both in RA and PsA/SpA [105]. In RA, 44% of samples 
exhibited positive staining for intracellular citrullinated proteins and 46% for MHC–HC gp39 
peptide complexes, whereas no staining for these markers was observed in PsA and SpA samples. 
No influences of disease modifying anti-rheumatic drug (DMARDs) and/or corticosteroid treatment 
was noted [120-123].  
Focusing on PsA, no significant differences were observed between PsA and SpA, and between 
oligoarticular and polyarticular PsA. Both PsA groups can be differentiated from RA on the basis of 
these same synovial features, suggesting that peripheral synovitis in PsA belongs to the SpA 
concept. 
 
6. Vascularization in Arthritis 
Neovascularization, or growth of new blood vessels from preexisting vessels of the synovium, is the 
hallmarks of synovitis. The formation of new blood vessels appears to be an essential pathogenic 
step for synovitis. Microscopical examinations of synovial biopsies show, that development of 
microvessels is the earliest sign of RA. This so called angiogenesis correlates with disease activity, 
and therefore several imaging modalities attempt to visualize those early vascular changes 
[124,125]. Studies in experimental models of arthritis even suggest that destruction of bone and 
cartilage may be more closely linked to angiogenesis then to pannus swelling. VEGF concentrations 
are elevated in RA and are known to correlate with disease activity and radiographic progression. 
Synovial tissues expressing VEGF show a significantly higher microvascular density than those not 
expressing it [126]. Synovial vascularization correlates with disease activity and aggressiveness 
[127]. 
The development of rheumatologic arthroscopy and microinvasively obtained tissue samples 
represent a significant step forward in investigating joint disease, especially the macro- and 
microscopic vascular changes characteristic of synovitis. Histopathological assessment of synovial 
vascular changes in chronic arthritis is of diagnostic and pathogenetic value [128]. 
Studies found distinct vascular patterns of synovium for PsA, SpA, reactive arthritis (ReA) and RA. 
RA patients had predominantly straight, branching vessels, whereas patients with PsA, SpA and 
ReA had predominantly tortuous, bushy vessels. Specific vascular growth factors may be involved 
[129]. Whereas vascularization degree was higher in PSA/SpA than RA, expression of adhesion 
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molecules on vessel walls did not differ between RA and SpA [105,119]. The blood vessels were 
preferentially seen in the superficial layers just beneath the synovial lining layer in both diseases.   
Whereas in RA, activity of synovial proliferation was confined to the areas surrounding cartilage, in 
PsA it was distributed more inhomogeneously in various parts of the joint. Nevertheless the 
vascularization was the most distinctive and reliable synovial feature [105,128-132]. Vascular 
patterns are not modified by disease duration or DMARD treatment [128].  
 
7. Vascular Imaging in Arthritis 
Overall, prompt diagnosis of arthritis, correct determination of prognosis and careful monitoring of 
disease activity is essential to reach modern treatment targets [133]. Specifically, imaging is helpful 
in clinical routine practice to early detect patients with mild clinical and laboratory inflammatory 
signs, but also to determine an aggressive course of disease, leading to a high degree of damage and 
destruction of joints and tendons, and to monitor response to treatment. Vascular imaging for 
angiogenesis may be more sensitive than clinical assessment of disease activity.  
Radiography is the traditional gold standard in assessing joint damage of RA patients and one of the 
ACR criteria published in 1987 [56]. CR is able to visualize the late signs of preceding disease 
activity but there is evidence for MRI and US being highly sensitive for early inflammatory and 
destructive changes in RA joints [134].  
MRI is known to be more sensitive than conventional clinical examination and radiography for 
detecting inflammatory and destructive joint changes in RA [135]. The exact assessment of the 
severity of active synovitis is an important issue because MRI studies have shown that the amount 
of pannus correlates with the aggressiveness of the disease [136]. Contrast-enhanced (CE-) MRI can 
distinguish between simple joint effusion and synovial proliferation. Synovial membrane 
enhancement in CE-MRI correlates strongly with histopathological cell infiltrates, blood vessel 
density and fractional area [137,138].  
Power Doppler ultrasound (PDUS) has demonstrated its utility in clinical practice for the 
assessment of disease activity by semiquantitative measurement of synovial vascularization [139]. 
PDUS correlates with histological findings in RA, proving its validity for qualitative evaluation of 
RA [140]. However, PDUS is limited in its ability to detect slow flow present in synovial 
neoangiogenesis. The use of contrast-enhanced US (CEUS) has ameliorated the study of synovial 
perfusion at microvascular level reaching performance of CE-MRI [141]. Recent studies 
demonstrated that CEUS is even superior to CE-MRI in the detection of synovitis [142-144]. 
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CE-ultrasound (CEUS) has drastically increased the sensitivity of PDUS enabling a better detection 
and quantification of inflammation, and consequently a more accurate distinction between inactive 
fibrous synovial proliferation and active synovitis, also in asymptomatic joints [145,146]. Further 
overall thickness measurements related to active synovitis were significantly improved by 
administering contrast agents [147]. 
With arthroscopy as reference, CEUS was found to be more useful than the unenhanced method in 
the recognition of increased vascularity of synovial villi [148]. The microvessel density measured 
by CEUS correlates exactly with angiographic and histologic findings [149-152]. Computer-aided 
validation and automated outlining of synovial boundaries enhance utility yield of CEUS in basal 
und follow-up assessment [153,154]. Therefore, CEUS appears particularly suitable to investigate 
possible distinct patterns of synovial vascularization in different forms of arthritis as demonstrated 
from histopathological studies. 
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Aims of the study 
To assess performance of automated versus manual classification system in differentiating RA from 
PsA arthritis by CEUS derived synovial vascularization patterns. To correlate clinical data and 
CEUS flow parameters. 
 
Material and methods 
Patients and clinical validation 
107 outclinic patients presenting with clinically active arthritis of finger joints were recruited from 
our Rheumatology Unit, University of Padova. 56 patients were affected from RA according to the 
classification criteria of 1987 or 2010 depending from disease duration [56,57]. 51 PsA patients 
were enrolled defined by CASPAR criteria [98]. 19 patients showed polyarticular, 11 oligoarticular, 
3 classic, 5 spondylitis subtype and 13 patients polyarticular disease with major erosions (mutilans). 
Patients‘ demographic data, disease duration and medical therapy were collected. Patients were 
validated clinically by DAS28, measurement of CRP and ESR and detection of RF and anti-CCP.  
All patient were asked for their informed consent. 
 
CEUS examination 
The most active joint was chosen for CEUS exams after collection of informed consent. As shown 
in Figure 1 the hands were water-immersed and steady probe was used to increase image quality as 
yet described [146]. CEUS was performed with US device (MyLab25; Esaote) equipped with 
Contrast tuned Imaging (CnTI; Esaote), using a low mechanical index. The mechanical index and 
acoustic pressure were set at 0.1 and 30 kPa, respectively. The contrast agent consisted of 
microbubbles filled by sulfur hexafluoride (SonoVue; Bracco International, Princeton, NJ). A 4.8 
ml bolus of contrast agent was injected into a peripheral vein of the opposite arm, followed by the 
injection of 20 ml saline solution. The selected joint was scanned in CnTI mode. The recording of 
the dynamic phases began simultaneously with the bolus injection and continued for 2 minutes.  
Sonograms were transferred to a PC workstation and both the anatomical B-mode image and the 
CnTI cineloop video were digitally stored for subsequent quantitative analysis or manual review.  
 
CEUS manual analysis 
Two in arthritis experienced radiologists unaware of patients‘ history manually assessed grade of 
synovial contrast using a semiquantitative three-point scale (0–2), as recommended by the IACUS 
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study group [147], where grade 0 indicates no visible synovial contrast enhancement, grade 1 a 
detectable enhancement but less than in the periarticular tissues, and grade 2 an enhancement 
definitely stronger than in the periarticular structures (Figure 2). 
Presumptive diagnosis of RA or PsA was expressed by radiologists considering typical 
histopathological features mentioned in the chapters before. Figure 3 shows exemplary CEUS 
studies for RA and PsA. RA is assumed to present with a more homogenous and synovial 
enhancement and faster time of contrast appearance due to linear and branching vessel architecture, 
whereas PsA with inhomogeneous enhancement both in synovial and perisynovial region 
representing entheses and capsules, and later contrast appearance due to tortuous, bushy vessels. 
After period of open training radiologists evaluated manually images for consistence with RA or 
not. Interobserver agreement was tested for manual CEUS grade and diagnosis. Additionally, 
radiologists outlined the boundaries of the synovial tissue on the gray-scale US images of each 
patient so that the subsequent analysis could be performed on the specific region of interest 
represented by the synovia, and on the region laying within 1 mm from the synovial boundaries 
(perisynovia), as it is shown on figure 4. 
 
Contrast kinetics model for automated CEUS analysis 
In the general case of perfusion problems, we can consider a bolus of non-diffusible tracer given at 
time       in a feeding vessel to a volume of interest: The individual particles of the tracer follow 
possibly different paths through the volume and their transit times thus have a distribution 
characteristic of the flow and the vascular structure. In the specific case of CEUS experiment, there 
is no diffusion of particles outside the vascular bed, and no perfusion of any tissue, so that we can 
reliably assume that each point in which some tracer (contrast dye) is detected corresponds to a 
vessel. Since there is no diffusion process involved, the kinetics of the tracer can be described by a 
Gamma-variate function as shown in figure 5 [155]. 
 
 ( )  {
     
    (    )
   
 
    
     
 
 
where    represents the contrast arrival time in the region of interest, and   and   are two 
parameters that modulate the raise and washout of the dye from the vascular bed, whereas    
accomodates the model for different peak intensity levels and   for different background (or 
baseline) intensity. 
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CEUS automated analysis 
Each examination is composed by an image     obtained with the gray-scale US, onto which the 
synovia has been manually identified, and by a video      
( )
 imaging the kinetics of the contrast 
medium. In order to provide a reliable analysis, it is needed that both the US head and the patient’s 
joint do not move during the acquisition of      
( )
, and that the anatomical information gathered 
from    can be perfectly superimposed to      
( )
. Since these conditions are hardly met in clinical 
settings, it is therefore necessary to register the gray-scale      image to each frame of the harmonic 
images      
( )
. In order to register the two different acquisition. By exploiting the high reflectivity in 
both modalities of the superficial tissues of the joint and of the bones, we firstly identified them on 
     by segmenting all pixels with intensity greater than the 95% percentile of the image intensities. 
With the same strategy we segment the pixels on each frame of        
( )
, and then we  estimate the 
displacement between     and       
( )
 , and then between each couple of subsequent frames       
( )
 
and       
(   )
, using the maximum of the phase-correlation. A representative result of the registration 
of the synovial region onto the CEUS data in an early and late enhancement phase is shown in 
figure 6. 
Moreover, in order to reduce the computational requirement of identifying the five parameters 
             describing the model of Eq. 1 for each pixel in the synovial regions, we chose to 
estimate the baseline intensity b as the mean intensity of the first 25 frames corresponding to the 
first 1s of the harmonic imaging, usually free from contrast signal .  
Given the   points    (     ) placed within the manually outlined synovial and perisynovial 
region, we obtain the corresponding   parameter estimates  ̂( )  [ ̂ ( )  ̂( )  ̂( )  ̂( )], by means 
of a non-linear least squares fitting of the parametric perfusion model  (   ) to the data      
( ) (  )  
From these parameters, we can derive a set of additional model characteristics as the peak value 
(    ( )       (   ̂ )), the time of peak (    ( )          (   ̂ )) the raise time (time 
      ( ) from the appearance   ( ) to reach half the peak), or the washout time (the time      ( ) 
from     ( ) that allows an intensity decrease of half the peak value).  
 
Pixel-based procedure: 
 ̅      
 
 
∑ ̂     ( )
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Region-based procedure: 
       ( )  
 
 
∑     
( )
(     )
 
 
 
Hence, for each video, at least mean value, the standard deviation, the      and      percentiles are 
computed for each model parameter and derived curve characteristic, so that 98 perfusion features 
are obtained (40 for the synovial perfusion and 37 for the perisynovial perfusion, 5 ratios 
synovial/perisynovial perfusion from pixel-based analysis, 16 perfusion features from region-based 
analysis). Pixel-based kinetics analyzed for synovia were time to appearance (t0), time to raise 
(traise), raise constant (a), 50% of raise (t1), time to peak (tmax), t2 (50% of washout), washout 
constant (b), time to washout (twash), amplification factor (A).  For these parameters mean, std, 25 
and 75 percentile were considered. Further synovial factors were peak value (ymax), peak from 
data, number of active clusters and pixels, mean and max cluster area, number of synovial pixels, 
mean, standard and total dye over time, blood flow (RBF) and volume (RBV). Pixel-derived 
kinetics analyzed for perisynovia were time to appearance (t0), time to raise (traise), raise constant 
(a), 50% of raise (t1), time to peak (tmax), t2 (50% of washout), washout constant (b), time to 
washout (twash), amplification factor (A).  For these parameters mean, std, 25 and 75 percentile 
were considered. Further synovial factors were peak value (ymax), peak from data, number of 
active clusters and pixels, mean and max cluster area, number of synovial pixels, mean, standard 
and total dye over time, blood flow (RBF) and volume (RBV). Ratios synovia/perisynovia were 
expressed for mean, standard and total dye and RBF and RBV. For region-based kinetics analyzed 
were t0, traise, a, t1, tmax, t2, b, twash, A, values of peak, peak from data, peak-base, signal 
intensity (SI), mean dye, RBF and RBV. 
In addition CEUS flow parameters, both pixel-based and region-based, were analyzed for 
correlations with DAS28, CRP, ESR, CEUS grade and diagnosis of radiologists. 
 
CEUS automated classification  
LDA classifier 
We trained a simple linear discriminant classifier (LDA) [156-158], that estimate the hyperplane 
that provide the best separation of the two classes of interest described by their features (kinetic 
parameters, serological and antibodies data …).  
Given a certain number of classes with supposedly different characteristics, LDA is a method for 
linearly mapping the high dimensional characteristics vector in a lower dimensional space, which 
maximize the separation between classes, supposing their distribution normal. LDA is based on the 
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maximization of a function   that is an indicator of the class separation. The most common of such 
measures involves the evaluation of the intra-class scatter matrix    and the inter-class scatter 
matrix   . Given N patients, M classes and a  x  vector   of F features each one belonging to one 
and only one class, the intra-class scatter matrix is: 
 
   ∑    
 
   
 
with    the a priori probability of the ith class, and    its covariance matrix. 
The inter-class scatter matrix    is: 
 
   ∑  (     )(     )
 
 
   
 
with  
 
 the mean feature vector of the ith class,  
 
 the global (weighted) mean. 
 
Thus, the class separation measure   maximixed by LDA is: 
       (  
    ) 
 
The  x   matrix   
     has rank M-1: a linear transformation mapping the original F-
dimensional features space into a new (M-1)-dimensional space, can therefore 
yields the same value for   while obtaining a lower dimensionality.  
In the specific case, since the classes of interest are 2 (rheumatoid and non-rheumatoid arthritis), 
M=2 and the LDA transformation maps the F dimensional feature vectors into a scalar number, to 
which a simple threshold can be applied to diagnose RA or non-RA arthritis. 
Given the vector     of the features belonging to patient    classified as class  , the transformed scalar 
feature is obtained through the linear transformation: 
         
And the final classification is obtained applying a threshold value   to    : 
 
          {
         
             
 
 
The threshold is chosen to minimize the classification error of the available data. 
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Feature selection 
In order to reduce the computational complexity and to discard non-informative features, the 
classifier has been wrapped with a greedy sequential forward feature selection [159], using as target 
score the accuracy of the classifier, that is defined as the fraction of samples (patients) that are 
correctly classified.  
By this means, the list of features used to estimate the LDA classifier is iteratively increased adding 
the single features that provides the greatest increase in the class-separability measure  . 
  
Cross-validation 
In order to test the robustness of the classifier, and to provide an estimate of its performance on new 
data, a leave-one-out cross validation has been performed. The N data are divided into a training set 
composed by N-1 samples (patients) and the testing set composed by the remaining sample. The 
LDA transformation matrix   and the optimal threshold   are estimated on the training set and then 
applied to the feature vector       in the testing set. The procedure is repeated N times, using as 
testing set a different patient and the remaining N-1 as training set. 
Mean (test) performance metrics as specificity, sensitivity and accuracy can be then estimated. 
  
Performance metrics 
The classifier is evaluated measuring its ability to classify RA patients as such (sensitivity), to 
classify non-RA patients as such (specificity), overall correct classification  (accuracy), to correctly 
predict that RA-classified patients are actually RA (positive predictive value), and that non-RA-
classified patients are actually non-RA (negative predictive value). 
Formally, defining as true positives (TP) the RA-patients classified as RA, the true negatives (TN) 
as the non-RA patients classified as non-RA, the false positives (FP) as the non-RA patients 
classified as RA, and finally as false negatives (FN) as the RA patients classified as non-RA, we 
have: 
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 Statistics 
For statistical analysis of classification, features selection, cross-validation, performance metrics,  
Student T and Chi Square Test as appropriate Matlab® (Matrix Laboratory; Math Works, Natick, 
Massachusetts USA) was used. 
 
Results 
Patients 
107 patients with active hand arthritis -56 with RA and 51 with PsA- were enrolled in the study and 
underwent CEUS examination. Patients’ characteristics are summarized in table 1. DAS28, ESR 
and presence of autoantibodies were significantly higher in RA than PsA (p < 0.05). CRP and ESR 
correlated with DAS28. Within PsA patients percentage of men were higher as expected for disease. 
Age and disease duration did not differ. Patients’ treatment with steroids, DMARDs and biologics 
did not differ between RA and PsA. 
 In 69.2% of cases CEUS analyzed joint was MCF, in 18.7% wrist and in 12.1% IFP joint. No 
patient reported adverse event because of US contrast administration.  
 
Manual CEUS interpretation of CEUS 
Interobserver agreement of radiologist for validation of CEUS grade (k = 0,98) and diagnosis (k =1) 
was excellent (data not shown). 42.1% of overall patients were scored with CEUS grade 2, 33% 
with grade 1 and 24.8% with grade 0. Patients with CEUS grade 2 presented significantly higher 
DAS28 than CEUS grade 1 patients, but only for RA group. 72.9 % of patients were diagnosed by 
radiologists to have RA, 27.1% to have PsA. CEUS diagnosis correlated with CEUS grades as 
radiologists tended to diagnose RA in front of higher CEUS grades.  
Diagnostic accuracy of manual validation by radiologists in differentiating RA from PsA was 0.69 
(sensitivity 0.71, specificity 0.66, NPV 0.62, PPV 0.72) as shown in table 2. Integrating clinical 
parameters DAS28, CRP, ESR did not enhance accuracy (data not shown). By adding data about 
positivity of autoantibodies the diagnostic accuracy of radiologists could be increased to 0.89 
(sensitivity 0.96, specificity 0.76, NPV 0.9, PPV 0.89) in training condition as shown in table 3, but 
not really  in test conditions (Table 4) with virtual de novo patients (leave one out cross validation) 
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Automated interpretation of CEUS 
All CEUS exams except 3 were available for further computed automated software analysis. Within 
the 98 flow parameters derived from automated software analysis 35 resulted statistically significant 
between RA and PsA.  
Classification accuracy using pixel-derived analysis was increasing by number of flow parameters 
included as shown in figure 7. The sum of 40 flow parameters constituted best constructed 
vascularization pattern to discriminate RA from PSA. Accuracy was 0.93 (sensitivity 0.91, 
specificity 0.94, NPV 0.90, PPV 0.94) during training. In Test situation with virtual de novo 
patients (leave one out cross validation) this would result in accuracy of 0.83 (sensitivity 0.84, 
specificity 0.77, NPV 0.80, PPV 0.81). Results are seen in table 5 and 6. 
The integration of information about RF and anti-CCP increased diagnostic accuracy and decreased 
number of flow parameters needed to construct discriminating vascularization pattern (Figure 9). 
With vascularization pattern using 28 flow parameters plus RF and anti-CCP accuracy resulted 0.99 
(sensitivity 0.98, specificity 1.0, NPV 0.97, PPV 1.0) in training and 0.93 (sensitivity 0.90, 
specificity 0.94, NPV 0.87, PPV 0.96) in test conditions, respectively shown in table 7 and 8. When 
RF or anti-CCP were used singularly accuracy decreased, but was better for RF (0,76) than anti-
CCP (0,63). 
The best flow parameters for the construction of vascularization pattern discriminating between RA 
and PsA were mean synovial raise time (faster in RA), mean synovial raise constant (lower in RA), 
time to synovial peak (faster in RA), mean synovial peak value (higher in RA), synovial active 
regions (more numerous in RA), mean dimension of synovial active regions (greater in RA), 
synovial and perisynovial blood volume (both greater in RA), synovia/perisynovia blood volume, 
flow (all higher in RA).  
A region-based analysis including 16 flow parameters as available in actually commercialized 
software packages showed no advances compared to manual analysis. Accuracy was of 0.73 
(sensitivity 0.73, specificity 0.72, NPV 0.69, PPV 0.75)  in differentiating RA from PsA in training 
and 0,61 (sensitivity 0.51, specificity 0.66, NPV 0.53, PPV 0.64)  in test conditions as shown in 
table 9 and 10. 
No correlations were detected between software derived kinetics and CRP, ESR and DAS28.  
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Discussion 
The 2 major and clinically most important primary inflammatory rheumatic diseases which affect 
small hand and feet joints are RA and PsA. RA and PsA are both common diseases in general 
population and have distinct pathologic, clinic, serologic and prognostic features.  
RA is characterized by primary synovial inflammation and transformation in tumor-like pannus 
with highly destructive potential. Systemic inflammation, specific autoantibodies and erosions are 
often and early detectable by blood exams and different imaging modalities such as CR, US, MRI. 
On the other side PsA is associated with pathognomonic skin and nail disease. Primary side of 
inflammation are entheses and perisynovial structures. Specific autoantibodies up to now are not 
known, and systemic inflammation is often absent. Radiologic features characteristically include 
marginal erosions and bone regeneration and proliferation, absolutely absent in RA. RA compared 
to PsA is a destructive polyarthritis and requires early diagnosis and treatment including highly 
priced biologics to avoid irreversible invalidation. Nevertheless correct diagnosis is not as easy as 
supposed from this paradigmatic view of both disease entities. In particular at disease beginning 
difference may by more subtle. Further antibodies and systemic inflammation are not always 
present in RA. PsO analogously can be absent or appear years after or before arthritis or result only 
from family history. Last not least PsA can mimic RA. In fact PsA can present with or evolve to 
polyarthritis (simil-rheumatoid form) or show erosions (20% of cases) and important destructions 
(mutilans form).  
The evolution of imaging techniques allowed better insights in anatomy and pathology of arthritis. 
CR is the traditional gold standard in assessing joint damage of RA, but works poorly in early RA. 
However, this technique has a number of limitations such as low contrast resolution, obscuring 
superimposition of projections and the use of ionizing radiation. Scintigraphy is highly sensitive for 
inflammatory hyperemia within the intraarticular and paraarticular soft tissues as well as for bone 
marrow hyperemia and increased osteoblastic activity, but specificity is low and requires al least 
combination with CR, because it is positive in etiologically quite different joint diseases [160,161]. 
An advantage of scintigraphy, even when compared with routine MRI (with exception of whole 
body MRI) is its ability to demonstrate multiple sites of inflammation.  
MRI depicts soft tissue changes and damage to cartilage and bone earlier and better than CR does. It 
is an excellent tool to assess synovial swelling and volume. CE-MRI is used to identify vascularized 
synovial proliferation and erosions. Further advantage of MRI for RA diagnosis is the quantification 
of bone marrow edema as a forerunner of erosions, direct cartilage visualization as well as 
inflammatory activity of inflamed synovial membrane [162,163]. US is an important imaging 
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modality for evaluation of RA and PsA. US, especially with use of highly sensitive Doppler 
imaging has high soft tissue contrast resolution. Sensitivity of US for demonstration of early 
synovitis and tenosynovitis as well as for evaluation of synovial vascularization is comparable to 
MRI. It is also of sensitivity for presentation of peripheral bone erosions [164,165]. MRI and US 
exhibited high specificities in detecting bone erosions in RA, even in radiographically non-eroded 
joints, when CT was used as the reference method [166]. 
In parallel attempts to differentiate arthritis forms by specific imaging features were tried. 
Exemplary, the presence of MRI synovitis and erosion and bone scintigraphic pattern compatible 
with RA showed 100% specificity for a diagnosis of RA at 2 year follow-up in patients with 
unclassified arthritis after standard validation with clinic, biochemical and radiographic 
examinations [167]. Accuracy combing both techniques was therefore 84%. MRI synovitis and 
erosion alone resulted in specificity of 87% and accuracy of 80%. RA-pattern on scintigraphy had  
only specificity of 74% and accuracy of 71%.  
Using CE-MRI of hands and feet in patients with PsA, inflammatory changes were studied  to 
define several subgroups and to present some specific findings important for early differential 
diagnosis between PsA and RA. A major subgroup of PsA patients with peripheral arthritis 
presented with wide spread soft tissue involvement extending well beyond the joint capsule and was 
clearly different from RA. The abnormalities were predominately extra-articular comprising 
thickened collateral ligaments, enthesitis at the insertions of the collateral ligaments and joint 
capsules, spreading to the surrounding soft tissues. Joint inflammation was asymmetrical, single ray 
distribution of all the joints of a single digit and DIP joint involvement were frequent.  Dactylitis 
consistent with combinations and degrees of arthritis, enthesitis at the insertions of the collateral 
ligaments and joint capsules, tenosynovitis and inflammation of the surrounding soft tissues was 
demonstrated frequently. MRI findings of predominately extra-articular inflammatory involvement 
in PsA in connection with increased bone density (periostitis, osteitis) on CR, cases with prevalence 
of productive changes, resulted prognostically more favorable. On the other side in more aggressive 
rheumatoid-like PsA subgroup, CE-MRI was not able to identify specific features. Both RA and 
rheumatoid-like PsA had a typical symmetrical distribution with affection of the PIP, MCP and 
MTP joints and sparing of the DIP joints. The hallmarks synovitis and subchondral bone marrow 
inflammation were present in both disease entities.  Bare areas and subchondral parts of the joints 
resulted to be preferential targets. Hyperemia of the soft tissue structures and bone marrow were 
localized and not as intense, and inflammatory changes were confined within the joint capsule, 
involving both sides of the joint [168]. 
44 
 
The areas of contrast enhancement by MRI were indistinguishable for PsA and RA in the joint 
synovial membrane and flexor tendons, whereas were significantly higher in PsA for the first and 
second extensor compartments, and for RA in the extensor carpi ulnaris region [169]. Erosions were 
statistically more frequent in patients with RA and periostitis in patients with PsA as demonstrated 
by CE-MRI, but no difference was found in the frequency of synovitis, although carpometacarpal 
MCF joints were affected more frequently in RA and PIP in PsA [170]. 
These studies confirm the feasibility to discriminate between RA and PsA especially using para-
articular characteristics and bone features found in PsA and not in RA. On the other hand they 
showed lack of efficacy to differentiate between both disease entities by study of synovitis, 
although histopathological analyses clearly demonstrated distinct pathognomonic vascularization 
patterns between RA and PsA, both in its oligo- and polyarticular subgroup [119]. The explanation 
may be that contrast agents in MRI are not true intravascular agents, and are easily extravasated. 
They dependent from vascular perfusion but also vessel permeability resulting in leakage into the 
interstitial space [171]. Despite extremely high sensitivity, contrast agents used in CEUS persist in 
the vascular bed and do not leak into the extrasynovial compartments. CEUS can therefore provide 
a more accurate live picture of changes in the synovial vascularization [172].  
In our study for the first time feasibility of studying not invasively different vascularization patterns 
as histopathological proven for RA and PsA was demonstrated. The innovation we propose consists 
of studying arthritis by dynamic automated synovial imaging (DASI). CEUS examinations of active 
finger joints were analyzed for both RA and PsA by ad hoc developed software analysis program 
and semiquantitatively by radiologists.  
Clear differences in 98 contrast kinetics and therefore the possibility to construct a distinct 
vascularization pattern of RA and PsA were identified. The pixel-derived analysis resulted in high 
accuracy in diagnosing correctly RA and PsA: 0.93 in training and 0.83 in test conditions. The 
detection of distinct patterns was possible on one joint without ulterior data such as clinical data, 
joint involvement, DAS28, ERS and CRP. Adding data of autoantibodies enhanced accuracy to 
0.99 in training and 0.93 in test conditions. The informations derive from a single joint rising some 
criticism. However, we recently demonstrated that joint selection based on the patients referred pain 
identifies joint with most synovitis in CE-MRI [173]. Distinction between RA and PsA could not be 
achieved with contrast study curves in dynamic CE-MRI, where RA and PsA both oligo and 
polyarticular appeared with similar patterns [174]. Evidently more precise analysis including more 
flow parameters are necessary. This may explain less accuracy of region-based analysis (0.61) as 
available in actually commercialized software packs (e.g. Qontrast®) or manual CEUS 
interpretation (0.69) regardless of autoantibody status. 
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Manual interpretation of CEUS images were based on results from histopathological studies. 
Blinded radiologists showed accuracy of 0.69 in diagnosing RA or PsA with near 100% 
interobserver agreement. RA is assumed to present with a more homogenous and synovial 
enhancement and faster time of contrast appearance due to linear and branching vessel architecture, 
whereas PsA with inhomogeneous enhancement both in synovial and perisynovial region 
representing entheses and capsules, and later contrast appearance due to tortuous, bushy vessels.  
These assumptions and histopathological data are confirmed by pixel-based analysis. RA shows 
greater and more homogenous neovascularization in synovia (synovial mean peak, active regions, 
mean dimension of synovial active regions and blood volume) und perisynovia  (perisynovial blood 
volume) than PsA. In PsA inflammation is concentrated in perisynovial regions (lower 
synovia/perisynovia blood flow and volume). In RA vessels are straight and less tortuous than in 
PsA (lower synovial raise,  raise constant and  time to synovial peak).  
Disease activity (DAS28) was higher in RA versus PsA patients. This depends from more factors. 
First of all PsA contained mainly polyarticular but also oligoarticular subtypes. CRP and ESR  were 
often negative or low in PsA. Validation of DAS28 spares hip, ankle and feet joints, very often 
affected in PsA. Tendonitis and dactylitis involvement frequent in PsA is tricky to insert in DAS28 
joint count. DAS28 in general may not be adequate to measure disease activity in PsA except for 
simil-rheumatoid variant. On the other side PsA patients have been as frequently treated with 
steroids, DMARDs or biologics as RA patients as expression of similar disease severity. Patients 
measured by radiologists with CEUS grade 2 had higher DAS28 than those with grade 1.  
Radiologists tented to diagnose CEUS grad 2 more often to be RA. Probably signal intensity (SI) is 
a determinant factor in decisions of radiologists’ eyes and correlates well with semi-quantative PD 
scores [153]. Nevertheless automated CEUS flow parameters contrary to MRI do not correlate with 
classical disease activity parameters such as DAS28, CRP and ESR [153,173,174]. They represent 
new data independent from disease activity. 
 
Conclusion 
Development of DASI represents a new method to study vascularization in synovitis without the 
need of  histopathological specimens. DASI gives insights in the vascular engine of joint 
inflammation and destruction. DASI is an effective tool to differentiate RA from PsA.  
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Abbreviations 
A = amplification factor 
a = raise constant 
ACR = American College of Rheumatology  
ANA = anti-nuclear antibodies 
APC = antigen presenting cell 
APCA = anti-citrullinated protein antibodies  
APRIL = a proliferation inducing ligand 
BAFF = B cell activating factor 
CASPAR = ClASsification criteria for Psoriatic Arthritis 
CCP = cyclic citrullinated peptide  
CD = cluster of differentiation 
CE = contrast enhanced 
CEUS = contrast-enhanced ultrasound 
CnTI = contrast tuned imaging 
CR = conventional radiology 
CRP = C-reactive protein 
CSF = colony stimulating factor 
CTLA = cytotoxic T-lymphocyte antigen 
DASI = dynamic automated synovial imaging 
DCs = dendritic cells 
DIP = distal interphalangeal  
DKK = dickkopf 
DMARD = disease modifying anti-rheumatic drugs 
ESR = erythrocyte sedimentation rate 
EULAR = European League against Rheumatism 
FGF = fibroblast growth factor 
FLS = fibroblast-like synoviocytes 
gp = glycopeptide 
HC = human cartilage 
HLA = human leukocyte antigen 
HSP = heat shock protein 
ICAM = intercellular adhesion molecule 
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ICOS = inducible costimulator 
IL = interleukin 
INF = interferon 
LDA = linear discriminant classifier 
LFA = leucocyte function-associated antigen 
MCP = metacarpophalangeal 
MHC = major histocompatibility complex 
MIP = macrophage inflammatory protein 
MMP = matrix metalloproteinases 
MRI = magnetic Resonance Imaging 
MTF = metatarsophalangeal 
NF-κB = nuclear factor κB  
NHL = non Hodgkin lymphoma 
NK = natural killer 
NPV = negative predictive value 
OA = osteoarthritis 
OPG = osteoprotegerin  
PADI4 = peptidyl arginine deiminase, type IV 
PDGF = platelet derived growth factor 
PDS = power Doppler ultrasound 
PIP = proximal interphalangeal  
PPV = positive predictive value 
PsA = psoriatic arthritis 
PsO = psoriasis 
RA = rheumatoid arthritis 
RANKL = receptor activator of NF-κB ligand 
RBF = blood flow 
RBV = blood volume 
ReA = reactive arthritis 
RF = rheumatoid factor 
SI = signal intensity  
SpA = spondyloarthritis 
Std = standard deviation 
T0 = time to appearance  
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TCR = T cell receptor 
TGF = transforming growth factor 
Th = T helper 
TIMP = tissue inhibitors of metalloproteinases 
TLR = toll like receptor 
Tmax = time to peak 
TNF = tumor necrosis factor 
Traise = time to raise 
Treg = T regulator 
Twash = washout time 
US = ultrasound 
VEGF = vascular endothelial growth factor 
ymax= peak value 
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Figure 3: Distinct contrast enhancement in synovial and perisynovial region at peak value 
as seen in RA (left panel) and PsA (right panel) patient. 
 
 
  
Figure 4: Gray scale B-mode image of a metacarpophalangeal joint  (left panel), and the annotated 
synovial boundaries  (red, right panel) with the perisynovial region outline (green, right panel). 
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Figure 5:  
 
 
 
  
Figure 6: Registered synovial and perisynovial boundaries on different frames of the CEUS video. 
It is apparent the correct positioning both in the early enhancement phase (left panel) and in the late 
enhancement phase (right panel) of a representative PsA patient. 
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Figure 7:  Significantly different parameters were used for linear discriminant analysis to identify 
the transformation optimizing the linear separability of the two groups, and each patient was 
assigned to RA or non-RA with a Bayesian classification algorithm providing the a posteriori 
probability to belong to the RA or non-RA group. 
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Parameters RA  PsA  p 
n 
Sex female (%) 
Age (years) 
Disease duration (years) 
DAS28 
CRP mg/l 
ESR mm/h 
RF positive (%) 
Anti-CCP positive (%) 
No therapy (%) 
Steroid daily mg 
Steroid therapy (%) 
DMARDs therapy (%) 
Biologic therapy (%) 
56 
91,1 
55,5 ± 9,9 
11,1 ± 8,7 
4,98 ± 1,1 
18,7 ± 20,6 
44,5 ± 27,3 
67,1 
52,2 
11,9 
4,7 ± 3,7 
79,1 
59,7 
47,7 
51 
70,4 
52,6 ± 12,3 
10,6 ± 6,8 
3,69 ± 1,4 
14,6 ± 26 
28,1 ± 20 
11,3 
9,4 
3,8 
4 ± 4,2 
64,1 
52,8 
62,2 
 
< 0,05 
ns 
ns 
< 0,05 
ns 
< 0,05 
< 0,05 
< 0,05 
ns 
ns 
ns 
ns 
ns 
Table 1. 
 
 
 
 
CLINICAL DIAGNOSIS 
   
RA PSA 
MANUAL 
CEUS 
DIAGNOSIS 
RA 48 20 0.74 PPV 
PsA 21 18 0.62 NPV 
  
 0.71 0.66 
0.69 
Sensitivity Specificity 
Table 2: Diagnostic accuracy of radiologists on CEUS exams. 
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CLINICAL DIAGNOSIS 
   
RA PSA 
MANUAL 
CEUS 
DIAGNOSIS 
+RF/anti-CCP 
RA 44 6 0.89 PPV 
PsA 2 19 0.9 NPV 
  
 0.96 0.76 
0.89 
Sensitivity Specificity 
Table 3: Diagnostic accuracy of radiologists on CEUS exams plus RF and anti-CCP (training). 
 
 
CLINICAL DIAGNOSIS 
   
RA PSA 
MANUAL 
CEUS 
DIAGNOSIS 
RF/anti-CCP 
RA 38 15 0.72 PPV 
PsA 15 15 0.50 NPV 
  
 0.72 0.50 
0.67 
Sensitivity Specificity 
Table 4: Diagnostic accuracy of radiologists on CEUS exams plus RF and anti-CCP (test). 
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Figure 8: Diagnostic accuracy of pixel-derived automated analysis is increasing with number of 
parameters considered. 
 
CLINICAL DIAGNOSIS 
   
RA PSA 
PIXEL-BASED 
AUTOMATED 
CEUS 
DIAGNOSIS 
RA 51 3 0.94 PPV 
PsA 5 45 0.90 NPV 
  
 0.91 0.94 
0.93 
Sensitivity Specificity 
Table 5: Diagnostic accuracy of pixel-based automated CEUS analysis using 40 flow parameters 
(training). 
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CLINICAL DIAGNOSIS 
   
RA PSA 
PIXEL-BASED 
AUTOMATED 
CEUS 
DIAGNOSIS 
RA 47 11 0.81 PPV 
PsA 9 37 0.80 NPV 
  
 0.84 0.77 
0.83 
Sensitivity Specificity 
Table 6: Diagnostic accuracy of pixel-based automated CEUS analysis using 40 flow parameters 
(test). 
 
Figure 9: Diagnostic accuracy of pixel-derived automated analysis is increasing with number of 
parameters considered. Number of parameters needed is decreased by integrating RF and anti-CCP. 
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CLINICAL DIAGNOSIS 
   
RA PSA 
PIXEL-BASED 
AUTOMATED 
CEUS 
DIAGNOSIS 
+ FR/anti-CCP 
RA 47 1 1.0 PPV 
PsA 1 35 0.97 NPV 
  
 0.98 1.0 
0.99 
Sensitivity Specificity 
Table 7: Diagnostic accuracy of pixel-based automated CEUS analysis using 28 flow parameters 
plus FR and anti-CCP (training). 
 
 
CLINICAL DIAGNOSIS 
   
RA PSA 
PIXEL-BASED 
AUTOMATED 
CEUS 
DIAGNOSIS 
+RF/anti-CCP 
RA 43 2 0.96 PPV 
PsA 5 33 0.87 NPV 
  
 0.90 0.94 
0.93 
Sensitivity Specificity 
Table 8: Diagnostic accuracy of pixel-based automated CEUS analysis using 28 flow parameters 
plus FR and anti-CCP (test). 
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CLINICAL DIAGNOSIS 
   
RA PSA 
REGION-BASED 
AUTOMATED 
CEUS 
DIAGNOSIS 
RA 40 13 0.75 PPV 
PsA 15 34 0.69 NPV 
  
 0.73 0.72 
0.73 
Sensitivity Specificity 
Table 9: Diagnostic accuracy of region-based automated CEUS (training). 
 
 
CLINICAL DIAGNOSIS 
   
RA PSA 
REGION-BASED 
AUTOMATED 
CEUS 
DIAGNOSIS 
RA 29 18 0.64 PPV 
PsA 28 31 0.53 NPV 
  
 0.51 0.66 
0.61 
Sensitivity Specificity 
Table 10: Diagnostic accuracy of region-based automated CEUS (test). 
 
 
 
 
